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Abstract: There has been an increasing interest in the development of antimicrobial peptides (AMPs)
and their synthetic mimics as a novel class of antibiotics to overcome the rapid emergence of antibiotic
resistance. Recently, phenylglyoxamide-based small molecular AMP mimics have been identified as
potential leads to treat bacterial infections. In this study, a new series of biphenylglyoxamide-based
small molecular AMP mimics were synthesised from the ring-opening reaction of N-sulfonylisatin
bearing a biphenyl backbone with a diamine, followed by the conversion into tertiary ammonium
chloride, quaternary ammonium iodide and guanidinium hydrochloride salts. Structure–activity
relationship studies of the analogues identified the octanesulfonyl group as being essential for
both Gram-positive and Gram-negative antibacterial activity, while the biphenyl backbone was
important for Gram-negative antibacterial activity. The most potent analogue was identified to
be chloro-substituted quaternary ammonium iodide salt 15c, which possesses antibacterial activity
against both Gram-positive (MIC against Staphylococcus aureus = 8 µM) and Gram-negative bacteria
(MIC against Escherichia coli = 16 µM, Pseudomonas aeruginosa = 63 µM) and disrupted 35% of
pre-established S. aureus biofilms at 32 µM. Cytoplasmic membrane permeability and tethered
bilayer lipid membranes (tBLMs) studies suggested that 15c acts as a bacterial membrane disruptor.
In addition, in vitro toxicity studies showed that the potent compounds are non-toxic against human
cells at therapeutic dosages.
Keywords: 5-phenylisatin; antimicrobial peptide mimics; biphenylglyoxamide; quaternary ammonium
iodide; guanidinium hydrochloride; membrane disruption; antibiofilm
1. Introduction
Rapid emergence of antibiotic-resistant bacteria is a major global health concern. The Gram-positive
Staphylococcus aureus often has a high antibiotic-resistant rate, with approximately 65–85% of nosocomial
S. aureus infections associated with a beta-lactam-resistant strain [1,2]. When taking other bacterial
pathogens into account, there are more than 2.8 million individuals seriously infected by bacteria in
the United States every year, and 700,000 individuals are killed by drug-resistant bacteria around the
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world annually [3,4]. Since the late 1980s, there have been no new classes of antibiotics entering the
market, with new clinical drugs merely being the structural derivatives of existing antibiotics with the
same scaffolds [5–7]. These derivatives are prone to rapid resistance development and so can only
retard but not overcome the bacterial resistance dilemma. Hence, there is an urgent need to develop
novel classes of antibiotics to treat bacterial infection.
Another challenge encountered in battling bacterial infections is bacterial biofilms. The resistance
of bacteria in biofilms can be up to 1000 times higher than their planktonic from [8,9]. A biofilm is
a complex multicellular exopolysaccharide matrix that acts to protect the bacteria against harmful
conditions and also sequestrates a nutrient-rich area [8–10]. This exopolysaccharide matrix also
significantly reduces the penetrance of antibiotics to the bacteria embedded in the biofilm [11–13].
Furthermore, the presence of different phenotypes of bacteria in a biofilm creates a heterogeneity
in the growth rate and metabolism of the bacteria [14]. As conventional antibiotics mainly target
metabolically active and growing cells, slow or non-growing bacteria that survive the antibiotic
treatment can then reproduce and pass their resistance genes to their offspring. Moreover, the increased
rate of horizontal gene transfer in biofilms compared to planktonic cells can accelerate the speed
of resistance spread [8,15]. Approximately 65–80% bacterial infections are associated with biofilm
formations, and one of the most common pathogens found in biofilms is S. aureus [14,16,17]. To combat
biofilms, a few antibiofilm mechanisms have been developed in recent years such as to disrupt or
degrade the membrane potential of bacterial cells embedded in biofilms [18].
In recent years, there has been increasing interest in the development of antimicrobial peptides
(AMPs) as a new class of antibiotics. AMPs are naturally occurring peptides that serve as the first line of
the innate immune defence system in humans. They exhibit a broad spectrum of antimicrobial properties
against different microorganisms including bacteria, viruses and fungi [19–22]. The mechanism of
action of AMPs is mainly attributed to their facially amphiphilic structure. It is thought that the
cationic residues on one face of the AMP first bind electrostatically with the anionic bacterial membrane
surface. Then, the hydrophobic residues on the opposite face of the AMP aid in the insertion of
the entire AMP molecule by associating with the lipophilic interior of the bacterial cell membrane.
This disrupts the bacterial membrane, leading to the loss of membrane potential and leakage of cellular
contents, eventually killing the bacterial cell [19,23–25]. Unlike conventional antibiotics, AMPs act
via non-receptor interactions. Since a complete restructuring of the cell membrane is required for the
development of resistance, the chances of bacteria developing drug resistance to AMPs is low [19,26–28].
While AMPs possess high potency against bacterial cells, their deployment as drugs has been impeded
by their poor bioavailability, low proteolytic stability, high manufacturing cost and poor yield from
multi-step syntheses [19,29,30].
The limitations of AMPs have stimulated the development of AMP mimics such as α-peptides [31],
β-peptides [32,33] and peptoids [34,35]. In addition, there have been reports of several small molecular
AMP mimics such as anthranilamides [36], cationic peptoids [35], cholic acid derivatives [37] and
phenyleneethynylenes [38]. Similar to natural AMPs, these AMP mimics possess an amphiphilic
structure with good spatial separation between the hydrophobic and cationic groups. Among these
AMP mimics, Lytixar (LTX-109) 1 and Brilacidin (PMX-30063) 2 (Figure 1) have completed phase II
human clinical trials, suggesting that AMP mimics could be potential therapeutic agents for treating
bacterial infections [39].
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Figure 1. Structures of Lytixar (LTX-109) 1 and Brilacidin (PMX-30063) 2.
Isatin (indoline-2,3-dione) is a natural product found in plants of the genus Isatis [40].
Its derivatives have been reported to show a wide range of biological and pharmacological
properties, such as being antimicrobial, anti-inflammatory, anticancer, antiviral and acting as
analgesics [41]. Interestingly, N-acyl, N-aryl and N-sulfonylisatins 3 (Figure 2) can act as electrophiles
and be ring-opened by amines and alcohols to afford the corresponding phenylglyoxamides and
glyoxylic esters, respectively [40,42]. Since ring-opened phenylglyoxamide derivatives possess an
amide bond, they are potential candidates for the development of AMP mimics. Our group has
previously reported the synthesis of phenylglyoxamides (e.g., 4–5) derived from N-acylisatins and
N-sulfonylisatins [43–45]. Among these molecules, N-sulfonylphenylglyoxamide iodide salt 4b
and N-naphthoylphenylglyoxamide guanidinium salt 5 had moderate to good minimum inhibitory
concentrations (MIC) of 63 and 12 µM respectively, against Gram-positive S. aureus [43,44]. However,
these compounds gave no antibacterial activity against Gram-negative bacteria. Hence, we were
interested to structurally modify these compounds as part of the optimisation process.
Figure 2. Structures of N-substituted isatin 3 and phenylglyoxamide derivatives 4–5.
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Biphenyl is an important scaffold in drug development and is found in many drug molecules
and natural products [46,47]. Compounds containing the biphenyl moieties possess a wide variety of
biological properties, including being antibacterial and antifungal [48]. However, the low solubility
of biphenyl compounds in both water and common organic solvents is a major drawback which
impedes their synthesis and development for pharmaceutical applications. To address this issue,
Ol’khovik et al. incorporated the quaternary ammonium group in the development of antimicrobial
biphenyl molecules [49].
Recently, our group has demonstrated the importance of the biphenyl moiety in the development
of AMP mimics [50]. As the synthesis of biphenylglyoxamide derivatives has not been explored,
we report for the first time the synthesis of novel biphenylglyoxamide-based antimicrobial peptide
mimics from 5-phenylisatins. The antibacterial and antibiofilm activities of these compounds were
evaluated against S. aureus, Pseudomonas aeruginosa and Escherichia coli. The mechanism of action and
in vitro cytotoxicity of these compounds were also explored.
2. Results and Discussion
2.1. Design and Synthesis of Biphenyl Glyoxamide-Based Antimicrobial Peptide Mimics
In this work, a phenyl ring was installed at the 5-position of the phenylglyoxamide scaffold,
giving the biphenylglyoxamide scaffold. The terminal phenyl ring of this scaffold was modified
with electron-withdrawing halogen substituent (F and Cl) or a bulky naphthalenyl substituent to
investigate their effect on antibacterial activity. Four series of compounds with different cationic or
hydrophilic groups, namely glyoxamide derivatives (Series I), tertiary ammonium hydrochloride
salts (Series II), quaternary ammonium iodide salts (Series III) and guanidinium hydrochloride salts
(Series IV), were synthesised to compare the effect of cationic functionality on the biological activity
of the AMP mimics. Moreover, the N-octanesulfonyl group was appended to these AMP mimics as
the hydrophobic group, and this hydrophobic group was modified to the N-butanesulfonyl group or
N-naphthoyl group to study their effect on antibacterial activity.
These biphenylglyoxamide-based antimicrobial peptide mimics were synthesised according to
the pathways described in Schemes 1–4.
The biphenyl scaffold was incorporated into the molecules by the Suzuki-Miyaura cross-coupling
reaction. This was achieved by reacting 5-bromisatin 6 with different commercially available arylboronic
acids to afford 5-arylisatins 7 in good yields (57–86%) (Scheme 1).
Scheme 1. Synthesis of 5-arylisatins 7a–7d.
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Scheme 2. General synthetic scheme for the synthesis of series I glyoxamide derivatives 11–12, series II
tertiary ammonium chloride salts 13–14 and series III quaternary ammonium iodide salts 15–16.
A hydrophobic group was introduced into the scaffold by reacting 5-arylisatins 7a–7d with
an alkylsulfonyl chloride and triethylamine as base, furnishing N-alkylsulfonyl compounds 8a–8d
and 9a in good yields (52–72%) (Scheme 2). Subsequent nucleophilic ring-opening reaction of
N-alkylsulfonyl compounds 8a–8d and 9a with 3-dimethylaminopropylamine 10 afforded the
corresponding glyoxamides 11a–11d and 12a as series I compounds in excellent yields (94–99%).
The cationic group was installed by treating glyoxamides 11a–11d and 12a with 4 M HCl in dioxane to
give tertiary ammonium chloride salts 13a–13d and 14a as series II compounds in 92–99% yields or
with methyl iodide in tetrahydrofuran (THF) to give quaternary ammonium iodide salts 15a–15d and
16a as series III compounds in 90–95% yields. The analogous reactions with 5-butylisatin 7e as the
starting material generated the corresponding tertiary ammonium chloride salt 13e and quaternary
ammonium iodide salt 15e in 99% and 85% yields, respectively.
Alternatively, N-octanesulfonyl compounds 8a–8d were also ring-opened with N-Boc-1,
3-propanediamine 17 to give Boc-protected glyoxamides 18a–18d in excellent yields (95–97%)
(Scheme 3). Boc-protected glyoxamides 18a–18d were treated with 4 M HCl in dioxane to yield
aminoglyoxamides 19a–19d in good yields (64–90%). The subsequent guanylation reaction using
N,N’-di-Boc-1H-pyrazole-1-carboxamide and triethylamine afforded the corresponding Boc-protected
guanidine glyoxamides 21a–21d in moderate to good yields (31–77%). Finally, treating the Boc-protected
guanidine glyoxamides 21a–21d with trifluoroacetic acid in dichloromethane (DCM) followed by 4 M
HCl in dioxane provided the guanidinium hydrochloride salts 22a–22d as series IV compounds in
50–77% yields.
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Scheme 3. General synthetic scheme for the synthesis of series IV guanidinium hydrochloride salts 22.
Biphenyl derivatives 25–27 bearing a naphthoyl hydrophobic group in place of the alkylsulfonyl
group were also synthesised. Naphthoylation was achieved by treating 5-phenylisatin 7a with
sodium hydride and 2-naphthoyl chloride 23 to give the 5-phenyl-N-naphthoylisatin 24 in 35%
yield (Scheme 4). The nucleophilic ring-opening reaction of 5-phenyl-N-naphthoylisatin 24 with
3-dimethylaminopropylamine 10 gave amine 25, which was followed by salt conversion into the
corresponding tertiary ammonium chloride salt 26 and quaternary ammonium iodide salt 27 in 84%
and 79% yields, respectively.
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Scheme 4. Synthesis of N-naphthoylglyoxamide derivative 25 and its corresponding tertiary ammonium
chloride salt 26 and quaternary ammonium iodide salt 27.
2.2. Structure–Activity Relationship Study
The antibacterial activities of the synthesised antimicrobial peptide mimics were evaluated by
determining their minimum inhibitory concentration (MIC) against the Gram-positive S. aureus (SA38).
Moreover, quaternary ammonium iodide salts 15a–15e and guanidinium hydrochloride salts 22a–22d
were also tested against Gram-negative P. aeruginosa (PA01) and E. coli (K12) (Table 1). Generally,
the tested compounds showed lower antibacterial activity against Gram-negative strains compared to
Gram-positive S. aureus.
In the structure–activity relationship (SAR) analysis, the biphenyl system was beneficial for the
antibacterial activity of the analogues. Against Gram-positive S. aureus, the previously synthesised
unsubstituted parent and 5-bromosubstituted quaternary ammonium iodide salt 4 had an MIC value
of 250 and 63 µM respectively [43]. When a phenyl ring was substituted at the 5-position to give the
corresponding biphenyl analogue 15a, the MIC value decreased to 16 µM, indicating that this analogue
was nearly sixteen and four times as potent as the unsubstituted and 5-bromosubstituted compound,
respectively. Interestingly, having an n-butyl group at the 5-position of the phenyl ring, as in analogue
15e, also gave strong activity against S. aureus (MIC = 16 µM). Moreover, the biphenyl analogue 15a
showed MIC values of 125 and 32 µM against the Gram-negative P. aeruginosa and E. coli respectively,
while the unsubstituted parent compound 4a, 5-bromosubstituted 4b and 5-butylsubstituted 15e
analogues showed no antibacterial activity against these strains even at the highest concentration tested
(250 µM). This suggested that the biphenyl moiety is essential for the antibacterial activity against
Gram-negative bacteria, as the antibacterial ability was lost once the phenyl ring was removed.
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Table 1. Antibacterial activity (minimum inhibitory concentration, MIC) of biphenylglyoxamide
derivatives against different strains of bacteria.
Compound MIC (µM)
S. aureus P. aeruginosa E. coli
Glyoxamide derivatives
(Series I)
11a 24 ND ND
11b 16 ND ND
11c 16 ND ND
11d 16 ND ND
11e 63 ND ND
12a > 250 ND ND
25 > 250 ND ND
Tertiary ammonium chloride salts
(Series II)
13a 16 ND ND
13b 16 ND ND
13c 16 ND ND
13d 8 ND ND
13e 32 ND ND
14a > 250 ND ND
26 > 250 ND ND
Quaternary ammonium iodide salts
(Series III)
15a 16 125 32
15b 16 63 32
15c 8 63 16
15d 8 250 63
15e 16 > 250 > 250
16a > 250 ND ND
27 32 ND ND
Guanidinium hydrochloride salts
(Series IV)
22a 8 63 63
22b 8 63 16
22c 8 250 63
22d 8 > 250 > 250
pexiganan
(MSI-78) a 3.2–6.5 3.2–6.5 3.2–6.5
ND = Not determined; a previously reported values. [51].
After the biphenyl moiety was identified to be essential for antibacterial activity, modifications were
made to the terminal phenyl ring to investigate the effect of incorporating an electron-withdrawing
halogen atom at the para-position of the terminal phenyl ring as well as replacing the terminal
phenyl ring with a bulky naphthalene ring. Neither modification had a significant influence on
the antibacterial activity of the analogues against Gram-positive S. aureus, as all cationic analogues
(13a–13d, 15a–15d, 22a–22d) showed MIC values of 8 or 16 µM. Against the Gram-negative P. aeruginosa
and E. coli, the introduction of an electron-withdrawing halogen atom had no significant influence
or only slightly increased the antibacterial activity of the analogues. However, when the terminal
phenyl ring was replaced by a bulky naphthalene ring, the antibacterial activity of the analogue
against Gram-negative bacteria was significantly reduced (Table 1). Specifically, the activity of the
naphthalenyl-substituted quaternary ammonium iodide salt 15d was halved compared to 15a, while the
activity of the corresponding guanidinium hydrochloride salt 22d was completely lost. This suggested
that the steric hinderance arising from the bulky naphthalene group may reduce the activity of the
analogues against Gram-negative bacteria.
The effect of modifying the terminal group of the glyoxamide chain was also studied. In general,
Gram-positive antibacterial activity was weakest for the non-charged glyoxamide compounds 11a–11e.
Among the cationic compounds, the guanidinium hydrochloride salts 22a–22d were slightly more
potent against Gram-positive bacteria compared to the corresponding tertiary ammonium chloride salts
13a–13d and quaternary ammonium iodide salts 15a–15d. In this study, only quaternary ammonium
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iodide salts 15a–15e and guanidinium hydrochloride salts 22a–22d were tested against Gram-negative
P. aeruginosa and E. coli owing to their lower cytotoxicity, while the corresponding glyoxamide derivatives
11a–11e and tertiary ammonium chloride salts 13a–13e were not tested against these Gram-negative
strains due to their cytotoxicity against mammalian cells (see below). Against Gram-negative strains,
the quaternary ammonium iodide salts 15a–15e displayed slightly higher activities compared to their
corresponding guanidinium hydrochloride salts 22a–22d in most cases.
As the N-naphthoyl-phenylglyoxamide derivative 5 was previously reported to possess moderate
to high antibacterial activity [45], the effect of replacing the octanesulfonyl group by a naphthoyl group
was investigated. Upon replacing the octanesulfonyl group by a naphthoyl group, the antibacterial
activity of the ammonium chloride salt 26 was lost, while the corresponding quaternary ammonium
iodide salt 27 showed a two-fold decrease in activity (MIC = 32 µM against S. aureus; Table 1) compared
to the corresponding octanesulfonyl compound 15a. The tertiary ammonium chloride salt 14a and
quaternary ammonium iodide salt 16a bearing a butanesulfonyl group were also synthesised in
order to investigate the effect of alkyl chain length on antibacterial activity. Upon shortening the
octanesulfonyl group to butylsulfonyl (12a, 14a, 16a), the antibacterial activity was completely lost
(MIC > 250 µM against S. aureus; Table 1). These results show that the octanesulfonyl group was the
preferred hydrophobic group for high antibacterial activity.
Overall, the SAR analysis for these biphenylglyoxamide-based AMP mimics has demonstrated
the importance of the octanesulfonyl group for high antibacterial activity against Gram-positive
S. aureus (Figure 3). These biphenylglyoxamide-based AMP mimics showed excellent antibacterial
activity against S. aureus regardless of the substitution or bulkiness of the terminal aryl ring.
Against Gram-negative bacteria, the biphenyl scaffold is also essential for antibacterial activities
against P. aeruginosa and E. coli. Out of the four series of compounds, the guanidinium hydrochloride
series (series IV) showed the highest antibacterial activity against Gram-positive bacteria, while the
quaternary ammonium iodide series (series III) showed the highest antibacterial activity against
Gram-negative bacteria.
Figure 3. Summary of structure–activity relationships (SARs) for antibacterial activity.
2.3. Antibiofilm Activity
The ability of the more potent biphenyl-based antimicrobial peptide mimics (15c–15d, 22a–22d)
to disrupt established S. aureus biofilms was investigated at 1×, 2× and 4×MIC of the mimics using
a crystal violet staining assay (Figure 4). The naphthalene-bearing guanidinium hydrochloride
salt 22d showed the highest level of biofilm disruption among the tested compounds at 4× MIC
(32 µM), disrupting 50% of preformed S. aureus biofilms, whereas the fluoro-substituted guanidinium
hydrochloride salt 22b and the chloro-substituted quaternary ammonium iodide salt 15c disrupted
39% and 35% respectively, of preformed S. aureus biofilms at 4×MIC. The biofilm disruption ability of
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these three compounds (15c, 22b, 22d) are comparable to that of LL-37, a natural antimicrobial peptide
that is being tested in phase II clinical trials that can disrupt mature S. aureus biofilms by approximately
40% at 4× its MIC (32 µM) [52].
Figure 4. Percentage of remaining S. aureus biofilms after 24 h treatment with compounds 22d (top),
22b (middle) or 15c (bottom) at 1×, 2× and 4× of their MIC. Error bars represent the standard error of
triplicates (n = 3).
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The remaining three tested antimicrobial peptide mimics (15d, 22a, 22c) failed to disrupt any
performed S. aureus biofilms at any tested concentrations (Supplementary Figure S1), suggesting that
they are active against planktonic S. aureus cells but are unable to disrupt bacteria that are densely
packed in matrices of extracellular polymeric communities.
The chloro-substituted quaternary ammonium iodide salt 15c and the fluoro-substituted
guanidinium hydrochloride salt 22b, which had high antibacterial activity against E. coli, were also tested
for their ability to disrupt preformed E. coli biofilm at 4×MIC (64 µM). However, these compounds only
managed to disrupt an insignificant amount of the preformed E. coli biofilm (Supplementary Figure S2).
This difference may be due to the different extracellular polymeric substances used by these bacteria
to form biofilms. The biofilms of S. aureus are composed of β-1,6-N-acetyl-D-glucosamine polymer
and extracellular DNA, whereas the biofilms of E. coli are composed of β-1,6-N-acetyl-D-glucosamine
polymer, colanic acid and cellulose [53–57].
Overall, the guanidinium hydrochloride salts 22b, 22d and the quaternary ammonium iodide salt
15c were the most active antimicrobial peptide mimics against S. aureus biofilms.
2.4. Cytoplasmic Membrane Depolarisation
The mechanisms of action of the most active compounds were further explored using a membrane
dye release assay. It was hypothesised that the mechanism of action of cationic AMP mimics arises from
the electrostatic interactions between the cationic head group of the compounds and the negatively
charged bacterial cell membrane. In order to verify this hypothesis, 3,3′-dipropylthiadicarbocyanine
iodide (diSC3-5), a membrane potential sensitive dye, was employed to monitor bacterial cytoplasmic
membrane integrity in the presence of the compounds. This dye readily partitions to and aggregates in
the bacterial cell membrane, causing self-quenching of fluorescence when the bacterial cell membrane
is intact. However, if the test compound disrupts or induces pore formation in the bacterial cell
membrane, the membrane potential gradient would be lost and an increase in fluorescence intensity
would be observed due to the release of the dye from the bacterial cell membrane.
As shown in Figure 5, compounds 15c, 22b and 22d induced disruption of the cytoplasmic
membrane of S. aureus, as indicated by the increase of dye fluorescence in a time- and concentration-
dependent manner. Out of these three compounds, the quaternary ammonium iodide salt 15c was
the most effective bacterial cytoplasmic membrane disruptor, as evidenced by the largest increase
in fluorescence intensity at 1× and 2×MIC within 5 min. The increase in fluorescence intensity for
the other two guanidinium hydrochloride salts 22b and 22d was modest when compared to that of
the quaternary ammonium iodide salt 15c, suggesting they are less effective in disrupting bacterial
cytoplasmic membrane.
In addition to the cytoplasmic membrane dye release assay, the time-kill kinetic assay was
utilised to further investigate the mechanism responsible for the bactericidal effect of the AMP mimics
(Figure 6). The time-kill kinetic assay measures bacterial cell viability after the treatment of bacteria with
a compound, and hence can indicate the bactericidal activity of a compound over time. The bacterial
cell viability of all test compounds, 15c, 22b, 22d, against S. aureus was observed to be time- and
concentration-dependent in this assay, which resembled the results observed in the cytoplasmic
membrane dye release assay. In this assay, quaternary ammonium iodide salt 15c showed the highest
reduction (2-log and 1-log reductions, respectively) in bacterial numbers at 2× and 1×MIC, while the
other two guanidinium hydrochloride salts, 22b and 22d, showed smaller reductions (less than 1-log
reductions) of bacterial numbers. The trend in the activity of these compounds are consistent with
what was observed in the cytoplasmic membrane dye release assay.
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Figure 5. Cytoplasmic membrane disruption of S. aureus promoted by compounds 15c, 22b and 22d at
1× and 2× of their MIC. 10% DMSO was used as positive control.
Figure 6. Cell viability count of S. aureus in the presence of compound 15c, 22b and 22d at 1× and 2×
their MIC.
Overall, these results suggested that the AMP mimics could exert their antibacterial action via
permeating bacterial membranes, with the quaternary ammonium iodide salt 15c being the most
active AMP mimic. However, there might be other mechanisms of action as well, such as effect on
intracellular components, and these will be explored in future studies [58].
2.5. Lipid Bilayer Membrane Conduction
Tethered bilayer lipid membranes (tBLM), in conjunction with AC electrical impedance
spectroscopy, were used to assess the ability of selected potent compounds: 15c–15d, 22a,
and 22c–22d, to interact with cell membranes. [59,60] In zwitterionic 1-palmitoyl-2-oleoyl-sn-glycero-3
-phosphorylcholine (POPC) tBLMs, quaternary ammonium iodide salts 15c and 15d produced a
2.5× shift in membrane conductance at concentrations as low as 100 nM (Figure 7A). In contrast,
these changes are notably absent for 15c and 15d in membranes that contain 30% negatively charged
palmitoyl-oleoyl-phosphatidyglycerol (POPG) lipids, compared to other tested compounds (Figure 7B).
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Responses to low concentrations of the compounds (<1 µM) in zwitterionic membranes are thought
to be due to the compounds producing changes in lipid packing as they insert. Such alterations
in the area per lipid, according to the critical packing parameter model of antimicrobial-membrane
interactions [61], are associated with changes in the diameter of intrinsic pores in the lipid bilayer.
Figure 7. (A) Changes in membrane conductance caused by the addition of the compounds at
concentrations less than 1µM in (A) zwitterionic POPC tBLMs, and (B) tBLMs containing 30% negatively
charged POPG lipids. Large increases in membrane conduction due to select compounds are also
visible at higher concentrations (1–100 µM) in (C) zwitterionic POPC tBLMs, and (D) tBLMs containing
30% negatively charged POPG lipids. Large increases in membrane capacitance in (E) zwitterionic
tBLMs, and (F) negatively charged tBLMs, suggests that high concentrations of compounds lead to
massive disruption of the lipid bilayers. Error bars represent the standard errors from n = 3 replicates
for each compound, with the exception of 15c, which is n = 2.
At higher concentrations of the compounds, the changes of membrane conduction were more
pronounced, especially for compounds 15c, 15d and 22a in zwitterionic membrane (Figure 7C).
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Interestingly, these responses were lower in negatively charged membranes (Figure 7D). The significant
increases in membrane conduction suggested that these compounds possess lytic or surfactant-like
properties on membranes, in which these compounds sequester lipids from the lipid membrane bilayer
via micellisation and eventually disintegrate the membrane [61].
These findings are supported by the large increase of membrane capacitance in both zwitterionic
(Figure 7E) and negatively charged tBLMs (Figure 7F) upon treatment of the compounds 15c and 15d,
suggesting that these membranes have been disintegrated due to the saturating concentrations of these
particular compounds. Increases in membrane capacitance indicate a thinning of the lipid membrane
and/or the incorporation of a high dielectric, such as water, into the membrane. These results suggest a
diminishing of the membrane due to the removal of lipids from the lipid membrane bilayer brought by
the surfactant-like effect of compounds.
2.6. Cytotoxicity Activity
The cytotoxicity of biphenyl-based AMP mimics was determined in order to evaluate their utility
as antimicrobial agents. The in vitro toxicity of selected compounds (11a, 11d, 13a, 13c–13e, 15a–15e,
22a–22d) was assessed against MRC-5 normal human fibroblasts using the MTT assay. A dose-response
curve for each test compound was generated and their IC50 values were determined. The IC50 values
obtained were then used to calculate the therapeutic indices (IC50 value divided by MIC value) against
S. aureus, P. aeruginosa and E. coli for each the compound (Table 2). A higher therapeutic index
corresponds to a more selective antimicrobial agent.
Table 2. IC50 value of compounds against MRC-5 normal human lung fibroblasts and their therapeutic
indices with respect to different strains of bacteria.
Compound IC50 (µM)
Therapeutic Index
S. aureus P. aeruginosa E. coli
Glyoxamide derivatives 11a 28.2 1.18 N/A N/A
11d 14.2 0.89 N/A N/A
Tertiary ammonium
chloride salts
13a 25.0 1.56 N/A N/A
13c 25.5 1.59 N/A N/A
13d 19.7 2.46 N/A N/A
13e 23.6 0.74 N/A N/A
Quaternary ammonium
iodide salts
15a 50.7 3.17 0.41 1.59
15b 190 11.9 3.04 5.94
15c 95.8 12.0 1.53 5.99
15d 112 14.0 0.45 1.79
15e 101 6.31 N/A N/A
Guanidinium
hydrochloride salts
22a 75.5 9.44 1.21 1.21
22b 76.0 9.50 1.21 4.75
22c 95.0 11.9 0.38 1.52
22d 49.5 6.19 N/A N/A
N/A = Not applicable.
The glyoxamide compounds 11a and 11d were found to possess high toxicity (IC50 < 30 µM)
towards human cells, resulting in therapeutic indices of below 1.20 against S. aureus. This could be
due to the lack of cationic charge and the higher hydrophobicity of the compounds allowing them to
bind to the zwitterionic human cell membranes more easily [62]. The conversion of the glyoxamide
compounds 11a and 11d into their corresponding tertiary ammonium chloride salts 13a and 13d gave no
improvement in the toxicity of the compounds as they possess similar toxicity (IC50 < 30 µM) towards
human cells. However, owing to their lower MIC values, their therapeutic indices slightly increased
to 1.56–2.46 against S. aureus compared to the corresponding glyoxamide compounds. In contrast,
quaternary ammonium iodide salts 15a–15d and guanidinium hydrochloride salts 22a–22d showed
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lower toxicity (IC50 > 50 µM), with therapeutic indices of 3.17–13.98 against S. aureus. In particular,
compounds 15b, 15c, 15d, 22a, 22b and 22c with therapeutic indices above 9 against S. aureus are
promising antimicrobial agents as they are likely to be non-toxic to human cells at the therapeutic
dosages required to inhibit bacterial growth.
Owing to the lower potency of the quaternary ammonium iodide salts 15a–15d and guanidinium
hydrochloride salts 22a–22d against Gram-negative bacteria, their therapeutic indices against
P. aeruginosa and E. coli were significantly lower compared to that of S. aureus. Among these
compounds, the fluoro- and chloro-substituted quaternary ammonium iodide salts 15b–15c possessed
the highest therapeutic indices of around 6 against E. coli. Meanwhile, the fluoro-substituted quaternary
ammonium iodide 15b showed a therapeutic index of 3.04 against P. aeruginosa. Notably, compound
15b was also the least toxic (IC50 = 190 µM) against human cells among the compounds tested.
3. Materials and Methods
3.1. Synthesis of Analogues
3.1.1. General Information
All commercially available reagents were purchased from standard suppliers (Sigma Aldrich,
St Louis, MO, USA and Alfa-Aesar, Ward Hill, MA, USA) and used without further purification.
All reactions were performed under anhydrous condition with anhydrous solvent unless otherwise
specified, and anhydrous solvents were obtained using the PureSolv MD Solvent Purification
System. Reactions were monitored by thin-layer chromatography precoated with Merck silica
gel 60 F254 and visualisation was performed by using short or long wavelength of ultraviolet light.
Flash chromatography was carried out using Grace Davisil LC60A silica.
Melting points were measured using an OptiMelt melting point apparatus and are uncorrected.
1H and 13C NMR spectra were obtained in the specified solvents on a Bruker Avance III HD 400
(Bruker, Sydney, NSW, Australia) or Bruker Avance III 600 Cryo spectrometer (Bruker, Sydney, NSW,
Australia). Chemical shift (δ) are in parts per million (ppm) internally referenced to the solvent nuclei.
Multiplicities are assigned as singlet (s), broad singlet (bs), doublet (d), triplet (t), quartet (q), multiplet
(m) or a combination of these (e.g., dd, dt, td), and coupling constants (J) are reported in Hertz (Hz).
Infrared (IR) spectra were recorded using a Cary 630 FTIR spectrometer or NicoletTM iSTM 10 FTIR
spectrometer (Thermo Nicolet, Waltham, MA, USA) fitted with a diamond attenuated total reflectance
(ATR) sample interface. Low-resolution mass spectrometry was performed using a Thermo Fisher LCQ
Mass Spectrometer (Thermo Scientific, Waltham, MA, USA), while high-resolution mass spectrometry
(HRMS) was performed using a Thermo LTQ Orbitrap XL instrument (Thermo Scientific, Waltham,
MA, USA).
3.1.2. Synthetic Procedures and Experimental Characterisation Data
General Synthetic Procedure A for 5-arylisatins
To a solution mixture of 5-bromoisatin (1.0 equivalent) and the appropriate boronic acid
(1.1 equivalents) in degassed (for 30 min) 1:1 toluene/ethanol solution (40 mL), 2 M potassium
carbonate solution (2.0 equivalents; degassed for 30 min prior to addition) was added. The dark brown
solution was degassed for 30 min. Pd(PPh3)4 (0.01 equivalents) was then added to the solution mixture
and the reaction was heated at 90 ◦C under nitrogen atmosphere for 24 h. The brownish-black solution
was concentrated in vacuo. Water was then added to the reaction mixture and the resulting solution
was then acidified to pH 1 with HCl (2 M). The reddish-orange organic layer was extracted thrice
with dichloromethane (3 × 30 mL), washed with brine, dried over sodium sulphate and concentrated
in vacuo to give the crude product as a red solid. The crude product was purified by flash column
chromatography on silica to afford the product.
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5-Phenylindoline-2,3-dione (7a)
The titled compound was synthesised from 5-bromoisatin (2.02 g, 8.92 mmol), phenylboronic acid
(1.20 g, 9.83 mmol), potassium carbonate (2.50 g, 18.06 mmol) and Pd(PPh3)4 (116 mg, 0.100 mmol)
following general synthetic procedure A. The product was obtained as a red solid (1.72 g, 86%);
mp 250.3–250.4 ◦C; 1H NMR (400 MHz, DMSO-d6): δ 11.29 (bs, 1H, NH), 7.91 (dd, J = 8.2, 2.0 Hz, 1H,
ArH), 7.76 (d, J = 1.9 Hz, 1H, ArH), 7.67–7.63 (m, 2H, ArH), 7.48–7.42 (m. 2H, ArH), 7.39–7.33 (m,
1H, ArH), 7.01 (d, J = 8.2 Hz, 1H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 184.4 (CO), 159.6 (CO),
150.0 (ArC), 138.7 (ArC), 136.5 (ArCH), 134.9 (ArC), 129.0 (ArCH), 127.5 (ArCH), 126.2 (ArCH), 122.5
(ArCH), 118.4 (ArC), 112.7 (ArCH); IR (ATR): νmax 3273, 1759, 1729, 1617, 1508, 1473, 1432, 1308, 1254,
1203, 1183, 1099, 1022, 966, 910, 846, 770, 752, 730, 697, 654, 576, 517, 456, 424 cm−1; MS (+ ESI): m/z
246.08, [M + Na]+.
5-(4-Fluorophenyl)indoline-2,3-dione (7b)
The titled compound was synthesised from 5-bromoisatin (1.06 g, 4.70 mmol),
4-fluorophenylboronic acid (0.76 g, 5.40 mmol), potassium carbonate (1.31 g, 9.45 mmol) and Pd(PPh3)4
(55 mg, 0.048 mmol) following general synthetic procedure A. The product was obtained as a red solid
(0.68 g, 60%); mp 238.9–239.3 ◦C; 1H NMR (400 MHz, DMSO-d6): δ 11.13 (bs, 1H, NH), 7.87 (dd, J = 8.2,
2.0 Hz, 1H, ArH), 7.74 (d, J = 1.8 Hz, 1H, ArH), 7.72–7.65 (m, 2H, ArH), 7.31–7.23 (m, 2H, ArH), 6.99 (d,
J = 8.2 Hz, ArH); 13C NMR (100 MHz, DMSO-d6): δ 184.3 (CO), 161.8 (ArC), 159.5 (CO), 149.9 (ArC),
136.4 (ArCH), 135.2 (ArC), 133.9 (ArC), 128.3 (ArCH), 122.5 (ArCH), 118.4 (ArC), 115.8 (ArCH), 112.7
(ArCH); IR (ATR): νmax 3324, 3273, 1765, 1739, 1621, 1601, 1589, 1505, 1475, 1454, 1366, 1349, 1307, 1275,
1225, 1192, 1159, 1127, 1098, 1013, 967, 935, 914, 891, 843, 821, 752, 703, 652, 590, 566, 514, 497, 460, 448
cm−1; MS (+ ESI): m/z 264.00, [M + Na]+.
5-(4-Chlorophenyl)indoline-2,3-dione (7c)
The titled compound was synthesised from 5-bromoisatin (1.10 g, 4.87 mmol),
4-chlorophenylboronic acid (0.84 g, 5.40 mmol), potassium carbonate (1.37 g, 9.91 mmol) and Pd(PPh3)4
(78 mg, 0.068 mmol) following general synthetic procedure A. The product was obtained as a red solid
(0.72 g, 57%); mp 244.2–244.3 ◦C; 1H NMR (400 MHz, DMSO-d6): δ 11.15 (bs, 1H, NH), 7.90 (dd, J = 8.2,
2.0 Hz, 1H, ArH), 7.78 (d, J = 1.9 Hz, 1H, ArH), 7.71–7.67 (m, 2H, ArH), 7.52–7.47 (m, 2H, ArH), 7.00
(d, J = 8.2 Hz, 1H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 184.3 (CO), 159.5 (CO), 150.2 (ArC), 137.6
(ArC), 136.4 (ArCH), 133.5 (ArC), 132.3 (ArC), 128.9 (ArCH), 128.0 (ArCH), 122.5 (ArCH), 118.5 (ArC),
112.7 (ArCH); IR (ATR): νmax 3327, 3279, 1763, 1742, 1620, 1506, 1474, 1452, 1367, 1349, 1308, 1272, 1258,
1220, 1194, 1160, 1122, 1090, 1012, 966, 915, 842, 821, 811, 753, 742, 703, 655, 584, 567, 541, 513, 497, 460,
448 cm−1; MS (+ESI): m/z 280.08, [M + Na]+.
5-(Naphthalen-2-yl)indoline-2,3-dione (7d)
The titled compound was synthesised from 5-bromoisatin (1.05 g, 4.66 mmol), 4-naphthyllboronic
acid (0.94 g, 5.19 mmol), potassium carbonate (1.32 g, 9.51 mmol) and Pd(PPh3)4 (58 mg, 0.050 mmol)
following general synthetic procedure A. The product was obtained as a red solid (0.58 g, 46%);
mp 293.9–294.0 ◦C; 1H NMR (600 MHz, DMSO-d6): δ 11.17 (bs, 1H, NH), 8.24 (d, J = 1.7 Hz, 1H, ArH),
8.07 (dd, J = 8.2, 2.1 Hz, 1H, ArH), 8.01–7.97 (m, 2H, ArH), 7.95–7.92 (m, 2H, ArH), 7.84 (dd, J = 8.6,
1.9 Hz, 1H, ArH), 7.56–7.50 (m, 2H, ArH), 7.05 (dd, J = 8.2, 0.5 Hz, 1H, ArH); 13C NMR (150 MHz,
DMSO-d6): δ 184.4 (CO), 159.6 (CO), 150.0 (ArC), 136.7 (ArCH), 136.0 (ArC), 134.7 (ArC), 133.3 (ArC),
132.2 (ArC), 128.6 (ArCH), 128.2 (ArCH), 127.5 (ArCH), 126.5 (ArCH), 126.2 (ArCH), 124.7 (ArCH),
124.6 (ArCH), 122.7 (ArCH), 118.6 (ArC), 112.8 (ArCH); IR (ATR): νmax 3252, 1753, 1732, 1616, 1490,
1459, 1429, 1389, 1344, 1305, 1270, 1250, 1195, 1154, 1119, 980, 905, 891, 863, 846, 808, 752, 698, 636, 622,
598, 577, 560, 525, 496, 474, 460, 443 cm−1; HRMS (+ ESI): Found m/z 296.0682 [M + Na]+, C18H11NO2Na
required 296.0682.
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General Synthetic Procedure B for N-sulfonylisatins
To a solution of 5-substituted isatin (1.0 equivalent) in dichloromethane (20 mL), triethylamine
(1.1 equivalents) was added at 0 ◦C under nitrogen atmosphere. The reaction mixture was stirred at
0 ◦C for 20 min. 1-Octanesulfonyl chloride or 1-butanesulfonyl chloride (1.0 equivalent) was then
added slowly dropwise to the reaction mixture at 0 ◦C with stirring. The reaction mixture was then
stirred at room temperature for 3 h. After completion of the reaction, the resulting mixture was
concentrated in vacuo and washed with methanol to afford the product.
1-(Octylsulfonyl)-5-phenylindoline-2,3-dione (8a)
The titled compound was synthesised from 5-phenylindoline-2,3-dione 7a (1.70 g, 7.62 mmol),
triethylamine (1.20 mL, 8.61 mmol) and 1-octanesulfonyl chloride (1.50 mL, 7.67 mmol) following general
synthetic procedure B. The product was obtained as a yellow solid (1.58 g, 52%); mp 131.9-132.2 ◦C; 1H
NMR (400 MHz, DMSO-d6): δ 8.08 (dd, J = 8.5, 2.1 Hz, 1H, ArH), 7.98 (d, J = 2.0 Hz, 1H, ArH), 7.80
(d, J = 8.5 Hz, 1H, ArH), 7.75–7.71 (m, 2H, ArH), 7.50 (t, J = 7.8 Hz, 2H, ArH), 7.41 (t, J = 7.4 Hz, 1H,
ArH), 3.67–3.59 (m, 2H, CH2), 1.86–1.76 (m, 2H, CH2), 1.43–1.15 (m, 10H, CH2), 0.83 (t, J = 7.0 Hz, 3H,
CH3); 13C NMR (100 MHz, DMSO-d6): δ 178.7 (CO), 156.6 (CO), 146.1 (ArC), 138.0 (ArC), 137.0 (ArC),
135.9 (ArCH), 129.1 (ArCH), 128.1 (ArCH), 126.5 (ArCH), 122.4 (ArCH), 120.1 (ArC), 114.6 (ArCH),
53.7 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3 (CH2), 27.3 (CH2), 22.2 (CH2), 22.0 (CH2), 13.9 (CH3); IR (ATR):
νmax 3326, 3274, 2915, 2049, 1765, 1737, 1615, 1505, 1472, 1454, 1373, 1349, 1308, 1259, 1222, 1191, 1175,
1160, 1120, 1096, 1012, 967, 945, 913, 850, 821, 762, 754, 703, 651, 609, 592, 566, 532, 513, 497, 461, 448
cm−1; HRMS (+ ESI): Found m/z 422.1398 [M + Na]+, C22H25NO4SNa required 422.1397.
5-(4-Fluorophenyl)-1-(octylsulfonyl)indoline-2,3-dione (8b)
The titled compound was synthesised from 5-(4-fluorophenyl)indoline-2,3-dione 7b (0.54 g,
2.23 mmol), triethylamine (0.35 mL, 2.51 mmol) and 1-octanesulfonyl chloride (0.44 mL, 2.25 mmol)
following general synthetic procedure B. The product was obtained as a yellow solid (0.65 g, 70%);
mp 142.3–142.7 ◦C; 1H NMR (400 MHz, DMSO-d6): δ 8.06 (dd, J = 8.6, 2.2 Hz, 1H, ArH), 7.98 (d, J = 2.0,
1H, ArH), 7.82–7.74 (m, 3H, ArH), 7.36–7.28 (m, 2H, ArH), 3.67–3.59 (m, 2H, CH2), 1.86–1.75 (m, 2H,
CH2), 1.43–1.15 (m, 10H, CH2), 0.83 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (100 MHz, DMSO-d6): δ 178.7
(CO), 162.2 (ArC), 156.6 (CO), 146.1 (ArC), 136.0 (ArC), 135.8 (ArCH), 134.5 (ArC), 128.7 (ArCH), 122.5
(ArCH), 120.1 (ArC), 115.9 (ArCH), 114.6 (ArCH), 53.7 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3 (CH2), 27.3
(CH2), 22.2 (CH2), 22.0 (CH2), 13.9 (CH3); IR (ATR): νmax 3675, 2970, 2900, 1766, 1739, 1615, 1573, 1519,
1475, 1406, 1393, 1373, 1308, 1292, 1232, 1175, 1139, 1066, 1057, 1027, 944, 891, 856, 831, 784, 763, 726,
714, 701, 619, 605, 590, 567, 532, 497, 484, 466, 447 cm−1; HRMS (+ ESI): Found m/z 440.1303 [M + Na]+,
C22H24FNO4SNa required 440.1302.
5-(4-Chlorophenyl)-1-(octylsulfonyl)indoline-2,3-dione (8c)
The titled compound was synthesised from 5-(4-chlorophenyl)indoline-2,3-dione 7c (0.36 g,
1.41 mmol), triethylamine (0.22 mL, 1.58 mmol) and 1-octanesulfonyl chloride (0.28 mL, 1.43 mmol)
following general synthetic procedure B. The product was obtained as a yellow solid (0.32 g, 52%); mp
171.7–172.1 ◦C; 1H NMR (400 MHz, DMSO-d6): δ 8.08 (dd, J = 8.6, 2.2 Hz, 1H, ArH), 8.01 (d, J = 2.0 Hz,
1H, ArH), 7.82–7.75 (m, 3H, ArH), 7.54 (d, J = 8.6 Hz, 2H, ArH), 3.67–3.59 (m, 2H, CH2), 1.86–1.75 (m,
2H, CH2), 1.43–1.15 (m, 10H, CH2), 0.83 (t, J = 7.0 Hz, 3H, CH3); 13C NMR (100 MHz, DMSO-d6): δ
178.6 (CO), 156.6 (CO), 146.3 (ArC), 136.8 (ArC), 135.8 (ArCH), 135.6 (ArC), 132.9 (ArC), 129.0 (ArCH),
128.4 (ArCH), 122.5 (ArCH), 120.2 (ArC), 114.6 (ArCH), 53.7 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3 (CH2),
27.3 (CH2), 22.2 (CH2), 22.0 (CH2), 13.9 (CH3); IR (ATR): νmax 3675, 2970, 2900, 1772, 1746, 1614, 1587,
1568, 1468, 1405, 1394, 1369, 1306, 1287, 1241, 1183, 1168, 1139, 1076, 1066, 1057, 1011, 945, 892, 851, 818,
804, 765, 727, 707, 688, 601, 533, 509, 463, 454, 437 cm−1; HRMS (+ ESI): Found m/z 456.1007 [M + Na]+,
C22H24ClNO4SNa required 456.1007.
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5-(Naphthalen-2-yl)-1-(octylsulfonyl)indoline-2,3-dione (8d)
The titled compound was synthesised from 5-(naphthalen-2-yl)indoline-2,3-dione 7d (0.42 g,
1.54 mmol), triethylamine (0.24 mL, 1.72 mmol) and 1-octanesulfonyl chloride (0.30 mL, 1.54 mmol)
following general synthetic procedure B. The product was obtained as a yellow solid (0.50 g, 73%); mp
125.0-125.4 ◦C; 1H NMR (400 MHz, DMSO-d6): δ 8.33 (s, 1H, ArH), 8.23 (dd, J = 8.6, 2.1 Hz, 1H, ArH),
8.16 (d, J = 2.0 Hz, 1H, ArH), 8.05–8.00 (m, 2H, ArH), 7.98–7.94 (m, 1H, ArH), 7.93–7.88 (m, 1H, ArH),
7.85 (d, J = 8.6 Hz, 1H, ArH), 7.59–7.52 (m, 2H, ArH), 3.69–3.61 (m, 2H, CH2), 1.88–1.77 (m, 2H, CH2),
1.44–1.15 (m, 10H, CH2), 0.83 (t, J = 7.0 Hz, 3H, CH3); 13C NMR (100 MHz, DMSO-d6): δ 178.7 (CO),
156.7 (CO), 146.2 (ArC), 136.8 (ArC), 136.0 (ArCH), 135.2 (ArC), 133.3 (ArC), 132.4 (ArC), 128.7 (ArCH),
128.3 (ArCH), 127.5 (ArCH), 126.6 (ArCH), 126.5 (ArCH), 125.3 (ArCH), 124.6 (ArCH), 122.7 (ArCH),
120.2 (ArC), 114.7 (ArCH), 53.7 (CH2), 31.1 (CH2), 28.4 (CH2), 28.4 (CH2), 27.3 (CH2), 22.2 (CH2), 22.0
(CH2), 13.9 (CH3); IR (ATR): νmax 2923, 2852, 1766, 1737, 1615, 1578, 1488, 1460, 1424, 1374, 1306, 1293,
1270, 1259, 1235, 1198, 1173, 1136, 1110, 1094, 1038, 1017, 998, 953, 937, 922, 893, 872, 852, 824, 783, 763,
751, 744, 721, 700, 659, 632, 613, 589, 560, 532, 497, 474, 446 cm−1; HRMS (+ ESI): Found m/z 472.1554
[M + Na]+, C26H27NO4SNa required 472.1553.
5-Butyl-1-(octylsulfonyl)indoline-2,3-dione (8e)
The titled compound was synthesised from 5-butylindoline-2,3-dione 7e (0.40 g, 1.95 mmol),
triethylamine (0.30 mL, 2.15 mmol) and 1-octanesulfonyl chloride (0.39 mL, 1.99 mmol) following general
synthetic procedure B. The product was obtained as a yellow solid (0.41 g, 55%); mp 113.2–113.6 ◦C;
1H NMR (400 MHz, DMSO-d6): δ 7.64–7.53 (m, 3H, ArH), 3.62–3.56 (m, 2H, CH2), 2.62 (t, J = 7.7 Hz,
2H, CH2), 1.82–1.72 (m, 2H, CH2), 1.59–1.49 (m, 2H, CH2), 1.41–1.16 (m, 12H, CH2), 0.89 (t, J = 7.5 Hz,
3H, CH3), 0.84 (t, J = 7.0 Hz, 3H, CH3); 13C NMR (100 MHz, DMSO-d6): δ 178.9 (CO), 156.7 (CO), 145.1
(ArC), 139.5 (ArC), 137.8 (ArCH), 124.4 (ArCH), 119.4 (ArC), 114.0 (ArCH), 53.6 (CH2), 33.7 (CH2), 32.9
(CH2), 31.1 (CH2), 28.4 (CH2), 28.3 (CH2), 27.3 (CH2), 22.2 (CH2), 22.0 (CH2), 21.6 (CH2), 13.9 (CH3),
13.7 (CH3); IR (ATR): νmax 3854, 3675, 2968, 2911, 2362, 1762, 1737, 1615, 1584, 1483, 1467, 1406, 1393,
1372, 1293, 1250, 1241, 1223, 1177, 1152, 1134, 1116, 1077, 1066, 1057, 1027, 954, 868, 851, 782, 724, 706,
653, 605, 565, 532, 484, 462, 446 cm−1; HRMS (+ ESI): Found m/z 402.1711 [M + Na]+, C20H29NO4SNa
required 402.1710.
1-(Butylsulfonyl)-5-phenylindoline-2,3-dione (9a)
The titled compound was synthesised from 5-phenylindoline-2,3-dione 7a (0.45 g, 1.92 mmol),
triethylamine (0.30 mL, 2.15 mmol) and 1-butanesulfonyl chloride (0.25 mL, 1.93 mmol) following
general synthetic procedure B. The product was obtained as a yellow sticky solid (0.23 g, 34%); 1H
NMR (400 MHz, DMSO-d6): δ 8.08 (dd, J = 8.6, 2.2 Hz, 1H, ArH), 7.98 (d, J = 2.1 Hz, 1H, ArH), 7.80
(d, J = 8.6 Hz, 1H, ArH), 7.75–7.71 (m, 2H, ArH), 7.50 (t, J = 7.8 Hz, 2H, ArH), 7.41 (t, J = 7.3 Hz, 1H,
ArH), 3.67–3.60 (m, 2H, CH2), 1.85–1.76 (m, 2H, CH2), 1.47–1.36 (m, 2H, CH2), 0.88 (t, J = 7.4 Hz, 3H,
CH3); 13C NMR (100 MHz, DMSO-d6): δ 178.7 (CO), 156.6 (CO), 146.1 (ArC), 138.0 (ArC), 137.0 (ArC),
135.9 (ArCH), 129.1 (ArCH), 128.0 (ArCH), 126.5 (ArCH), 122.4 (ArCH), 120.1 (ArC), 114.6 (ArCH),
53.5 (CH2), 24.1 (CH2), 20.7 (CH2), 13.3 (CH3); IR (ATR): νmax 3196, 2961, 2873, 1777, 1736, 1648, 1615,
1588, 1508, 1485, 1472, 1455, 1399, 1368, 1339, 1310, 1293, 1270, 1241, 1183, 1171, 1139, 1117, 1040, 1000,
982, 949, 917, 842, 758, 734, 694, 674, 651, 620, 602, 579, 556, 532, 516, 464, 426 cm−1; HRMS (+ ESI):
Found m/z 366.0771 [M + Na]+, C18H17NO4SNa required 366.0770.
General Synthetic Procedure C for Glyoxamide Derivatives
To a solution of N-sulfonylisatin (1.0 equivalent) in dichloromethane (5 mL),
3-dimethylaminopropylamine (1.0 equivalent) was added at 0 ◦C. The reaction mixture was stirred at
room temperature for 6 h. After completion of the reaction, water was added to the reaction mixture
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and the product was extracted into dichloromethane (3 × 30 mL), washed with brine, dried over
anhydrous sodium sulphate and concentrated in vacuo to afford the product.
N-(3-(Dimethylamino)propyl)-2-(4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamide (11a)
The titled compound was synthesised from 1-(octylsulfonyl)-5-phenylindoline-2,3-dione 8a (0.11 g,
0.28 mmol) and 3-dimethylaminopropylamine (35µL, 0.28 mmol) following general synthetic procedure
C. The product was obtained as a yellow oil (0.13 g, 96%); 1H NMR (400 MHz, CDCl3): δ 8.78 (bs, 1H,
NH), 8.72 (d, J = 1.9 Hz, 1H, ArH), 7.87–7.80 (m, 2H, ArH), 7.60–7.55 (m, 2H, ArH), 7.47–7.41 (m, 2H,
ArH), 7.39–7.34 (m, 1H, ArH), 3.53 (t, J = 6.0 Hz, 2H, CH2), 3.21–3.15 (m, 2H, CH2), 2.55 (t, J = 6.2 Hz,
2H, CH2), 2.33 (s, 6H, CH3), 1.86–1.76 (m, 4H, CH2), 1.43–1.15 (m, 10H, CH2), 0.85 (t, J = 6.6 Hz, 3H,
CH3); 13C NMR (100 MHz, CDCl3): δ 192.0 (CO), 162.8 (CO), 140.9 (ArC), 139.1 (ArC), 135.8 (ArC),
134.9 (ArCH), 133.6 (ArCH), 129.1 (ArCH), 127.9 (ArCH), 127.0 (ArCH), 120.0 (ArC), 118.6 (ArCH), 58.6
(CH2), 52.7 (CH2), 45.2 (CH3), 39.8 (CH2), 31.8 (CH2), 29.1 (CH2), 29.0 (CH2), 28.2 (CH2), 25.3 (CH2),
23.5 (CH2), 22.7 (CH2), 14.2 (CH3); IR (ATR): νmax 3327, 3274, 2924, 2854, 1765, 1738, 1616, 1508, 1476,
1395, 1367, 1308, 1261, 1225, 1195, 1143, 1098, 1013, 967, 935, 821, 760, 698, 655, 585, 566, 514, 497, 460,
448 cm−1; HRMS (+ ESI): Found m/z 502.2734 [M + H]+, C27H40N3O4S required 502.2734.
N-(3-(Dimethylamino)propyl)-2-(4′-fluoro-4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-
2-oxoacetamide (11b)
The titled compound was synthesised from 5-(4-fluorophenyl)-1-(octylsulfonyl)indoline-2,3-dione
8b (0.13 g, 0.32 mmol) and 3-dimethylaminopropylamine (40µL, 0.32 mmol) following general synthetic
procedure C. The product was obtained as a yellow oil (0.16 g, 99%); 1H NMR (400 MHz, CDCl3): δ
8.86 (bs, 1H, NH), 8.71 (d, J = 2.2 Hz, 1H, ArH), 7.84 (d, J = 8.7 Hz, 1H, ArH), 7.77 (dd, J = 8.7, 2.2 Hz,
1H, ArH), 7.56–7.50 (m, 2H, ArH), 7.16–7.09 (m, 2H, ArH), 3.53 (t, J = 6.0 Hz, 2H, CH2), 3.20–3.14 (m,
2H, CH2), 2.52 (t, J = 6.1 Hz, 2H, CH2), 2.30 (s, 6H, CH3), 1.86–1.74 (m, 4H, CH2), 1.43–1.16 (m, 10H,
CH2), 0.85 (t, J = 7.2 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3): δ 191.8 (CO), 162.8 (ArC), 162.6 (CO),
140.9 (ArC), 135.3 (ArC), 134.8 (ArC), 134.7 (ArCH), 133.5 (ArCH), 128.6 (ArCH), 119.6 (ArC), 118.6
(ArCH), 116.1 (ArCH), 58.8 (CH2), 52.7 (CH2), 45.3 (CH3), 40.0 (CH2), 31.8 (CH2), 29.1 (CH2), 29.0
(CH2), 28.2 (CH2), 25.3 (CH2), 23.5 (CH2), 22.7 (CH2), 14.2 (CH3); IR (ATR): νmax 3675, 2970, 2923, 1659,
1635, 1571, 1491, 1393, 1338, 1261, 1222, 1200, 1139, 1066, 1057, 921, 821, 770, 724, 677, 595, 563, 520, 488,
419 cm−1; HRMS (+ ESI): Found m/z 520.2641 [M + H]+, C27H39FN3O4S required 520.2640.
2-(4′-Chloro-4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-N-(3-(dimethylamino)propyl)-
2-oxoacetamide (11c)
The titled compound was synthesised from 5-(4-chlorophenyl)-1-(octylsulfonyl)indoline-2,3-dione
8c (0.10 g, 0.24 mmol) and 3-dimethylaminopropylamine (30 µL, 0.24 mmol) following general synthetic
procedure C. The product was obtained as a yellow oil (0.12 g, 94%); 1H NMR (400 MHz, CDCl3): δ 8.88
(bs, 1H, NH), 8.75 (d, J = 2.2 Hz, 1H, ArH), 7.85 (d, J = 8.8 Hz, 1H, ArH), 7.78 (dd, J = 8.8, 2.3 Hz, 1H,
ArH), 7.54–7.47 (m, 2H, ArH), 7.43–7.38 (m, 2H, ArH), 3.52 (t, J = 6.0 Hz, 2H, CH2), 3.21–3.14 (m, 2H,
CH2), 2.53–2.48 (m, 2H, CH2), 2.29 (s, 6H, CH3), 1.86–1.74 (m, 4H, CH2), 1.42–1.16 (m, 10H, CH2), 0.85
(t, J = 7.1 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3): δ 191.7 (CO), 162.5 (CO), 141.2 (ArC), 137.6 (ArC),
134.6 (ArCH), 134.4 (ArC), 134.0 (ArC), 133.5 (ArCH), 129.3 (ArCH), 128.2 (ArCH), 119.6 (ArC), 118.6
(ArCH), 58.9 (CH2), 52.8 (CH2), 45.4 (CH3), 40.1 (CH2), 31.8 (CH2), 29.1 (CH2), 29.0 (CH2), 28.2 (CH2),
25.3 (CH2), 23.5 (CH2), 22.7 (CH2), 14.2 (CH3); IR (ATR): νmax 3675, 2969, 2922, 1773, 1746, 1636, 1615,
1507, 1482, 1467, 1394, 1338, 1260, 1198, 1140, 1076, 1066, 1012, 919, 852, 817, 773, 697, 600, 564, 539, 509,
492, 436, 426 cm−1; HRMS (+ ESI): Found m/z 536.2344 [M + H]+, C27H39ClN3O4S required 536.2344.
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N-(3-(Dimethylamino)propyl)-2-(5-(naphthalen-2-yl)-2-(octylsulfonamido)phenyl)-
2-oxoacetamide (11d)
The titled compound was synthesised from 5-(naphthalen-2-yl)-1-(octylsulfonyl)indoline-2,3-dione
8d (0.15 g, 0.33 mmol) and 3-dimethylaminopropylamine (42µL, 0.33 mmol) following general synthetic
procedure C. The product was obtained as a yellow oil (0.18 g, 96%); 1H NMR (400 MHz, CDCl3): δ
8.87 (d, J = 2.1 Hz, 1H, ArH), 8.85 (bs, 1H, NH), 8.02 (s, 1H, ArH), 7.98–7.84 (m, 5H, ArH), 7.71 (dd,
J = 8.5, 1.8 Hz, 1H, ArH), 7.55–7.47 (m, 2H, ArH), 3.55 (t, J = 5.9 Hz, 2H, CH2), 3.23–3.16 (m, 2H, CH2),
2.52 (t, J = 6.2 Hz, 2H, CH2), 2.30 (s, 6H, CH3), 1.87–1.75 (m, 4H, CH2), 1.43–1.17 (m, 10H, CH2), 0.85 (t,
J = 7.1 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3): δ 191.9 (CO), 162.7 (CO), 141.0 (ArC), 136.4 (ArC),
135.7 (ArC), 135.2 (ArCH), 133.9 (ArCH), 133.7 (ArC), 132.9 (ArC), 128.9 (ArCH), 128.4 (ArCH), 127.8
(ArCH), 126.7 (ArCH), 126.4 (ArCH), 125.7 (ArCH), 125.1 (ArCH), 119.7 (ArC), 118.7 (ArCH), 58.9
(CH2), 52.7 (CH2), 45.4 (CH3), 40.1 (CH2), 31.8 (CH2), 29.1 (CH2), 29.0 (CH2), 28.2 (CH2), 25.3 (CH2),
23.6 (CH2), 22.7 (CH2), 14.2 (CH3); IR (ATR): νmax 3675, 2924, 2855, 1767, 1739, 1641, 1616, 1577, 1492,
1462, 1394, 1333, 1262, 1234, 1201, 1142, 1098, 918, 892, 815, 747, 720, 670, 593, 561, 516, 475 cm−1; HRMS
(+ ESI): Found m/z 552.2895 [M + H]+, C31H42N3O4S required 552.2891.
2-(5-Butyl-2-(octylsulfonamido)phenyl)-N-(3-(dimethylamino)propyl)-2-oxoacetamide (11e)
The titled compound was synthesised from 5-butyl-1-(octylsulfonyl)indoline-2,3-dione 8e (0.15
g, 0.40 mmol) and 3-dimethylaminopropylamine (50 µL, 0.40 mmol) following general synthetic
procedure C. The product was obtained as a yellow oil (0.18 g, 95%); 1H NMR (400 MHz, CDCl3): δ
8.65 (bs, 1H, NH), 8.21 (d, J = 1.8 Hz, 1H, ArH), 7.67 (d, J = 8.5 Hz, 1H, ArH), 7.41 (dd, J = 8.6, 2.0 Hz,
1H, ArH), 3.56–3.48 (m, 2H, CH2), 3.14–3.08 (m, 2H, CH2), 2.63–2.52 (m, 4H, CH2), 2.34 (s, 6H, CH3),
1.86–1.71 (m, 4H, CH2), 1.63–1.52 (m, 2H, CH2), 1.41–1.17 (m, 12H, CH2), 0.92 (t, J = 7.3 Hz, 3H, CH3),
0.85 (t, J = 7.0 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3): δ 192.1 (CO), 163.0 (CO), 139.5 (ArC), 137.6
(ArC), 136.7 (ArCH), 134.6 (ArCH), 119.6 (ArC), 118.5 (ArCH), 58.6 (CH2), 52.4 (CH2), 45.2 (CH3), 39.6
(CH2), 34.9 (CH2), 33.6 (CH2), 31.8 (CH2), 29.1 (CH2), 29.0 (CH2), 28.2 (CH2), 25.3 (CH2), 23.5 (CH2),
22.7 (CH2), 22.4 (CH2), 14.2 (CH3), 14.0 (CH3); IR (ATR): νmax 3674, 2968, 2922, 1609, 1497, 1458, 1405,
1393, 1331, 1256, 1141, 1066, 1057, 934, 834, 781, 732, 668, 562, 520 cm−1; HRMS (+ ESI): Found m/z
482.3047 [M + H]+, C25H44N3O4S required 482.3047.
2-(4-(Butylsulfonamido)-[1,1′-biphenyl]-3-yl)-N-(3-(dimethylamino)propyl)-2-oxoacetamide (12a)
The titled compound was synthesised from 1-(butylsulfonyl)-5-phenylindoline-2,3-dione 9a
(0.15 g, 0.44 mmol) and 3-dimethylaminopropylamine (55 µL, 0.44 mmol) following general synthetic
procedure C. The product was obtained as a yellow oil (0.18 g, 93%); 1H NMR (400 MHz, CDCl3):
δ 8.81 (bs, 1H, NH), 8.73 (d, J = 2.0 Hz, 1H, ArH), 7.87–7.80 (m, 2H, ArH), 7.60–7.55 (m, 2H, ArH),
7.44 (t, J = 8.0 Hz, 2H, ArH), 7.39–7.33 (m, 1H, ArH), 3.53 (t, J = 6.2 Hz, 2H, CH2), 3.22–3.15 (m, 2H,
CH2), 2.51 (t, J = 6.2 Hz, 2H, CH2), 2.29 (s, 6H, CH3), 1.84–1.74 (m, 4H, CH2), 1.47–1.36 (m, 2H, CH2),
0.90 (t, J = 7.3 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3): δ 192.0 (CO), 162.7 (CO), 140.9 (ArC), 139.1
(ArC), 135.8 (ArC), 134.9 (ArCH), 133.6 (ArCH), 129.1 (ArCH), 127.9 (ArCH), 127.0 (ArCH), 119.6 (ArC),
118.6 (ArCH), 58.8 (CH2), 52.4 (CH2), 45.3 (CH3), 40.0 (CH2), 25.5 (CH2), 25.3 (CH2), 21.5 (CH2), 13.6
(CH3); IR (ATR): νmax 2960, 2871, 2363, 2345, 2183, 2160, 2049, 1978, 1870, 1773, 1734, 1710, 1701, 1685,
1670, 1663, 1654, 1647, 1636, 1617, 1578, 1570, 1560, 1541, 1534, 1522, 1508, 1482, 1466, 1459, 1449, 1395,
1330, 1259, 1194, 1142, 1096, 1025, 921, 794, 761, 733, 697, 681, 669, 616, 583, 555, 535, 477, 428 cm−1;
HRMS (+ ESI): Found m/z 466.2109 [M + H]+, C23H32N3O4S required 466.2108.
General Synthetic Procedure D for Tertiary Ammonium Chloride Salts
To a solution of glyoxamide derivative (1.0 equivalent) in diethyl ether (5 mL), 4 M HCl/dioxane
(5.0 equivalents) was added. The reaction mixture was stirred at room temperature for 20 min. After
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completion of reaction, the reaction mixture was concentrated in vacuo, washed thrice with diethyl
ether and freeze-dried to afford the product.
N,N-Dimethyl-3-(2-(4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamido)propan-1-aminium
chloride (13a)
The titled compound was synthesised from N-(3-(dimethylamino)propyl)-2-(4-(octylsulfonamido)-
[1,1′-biphenyl]-3-yl)-2-oxoacetamide 11a (33 mg, 0.066 mmol) and 4 M HCl/dioxane (0.10 mL, 0.40 mmol)
following general synthetic procedure D. The product was obtained as a yellow sticky solid (33 mg,
93%); 1H NMR (600 MHz, DMSO-d6): δ 10.25 (bs, 2H, NH), 9.03 (t, J = 5.8 Hz, 1H, NH), 8.01–7.98 (m,
2H, ArH), 7.67–7.60 (m, 3H, ArH), 7.52–7.48 (m, 2H, ArH), 7.40 (t, J = 7.4 Hz, 1H, ArH), 3.32 (t, J = 6.5
Hz, 2H, CH2), 3.24–3.20 (m, 2H, CH2), 3.12–3.07 (m, 2H, CH2), 2.73 (s, 6H, CH3), 1.97–1.90 (m, 2H,
CH2), 1.70–1.64 (m, 2H, CH2), 1.37–1.16 (m, 10H, CH2), 0.82 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (150
MHz, DMSO-d6): δ 192.1 (CO), 163.8 (CO), 138.3 (ArC), 137.9 (ArC), 135.9 (ArC), 132.9 (ArCH), 130.3
(ArCH), 129.2 (ArCH), 127.9 (ArCH), 126.5 (ArCH), 125.8 (ArC), 122.3 (ArCH), 54.4 (CH2), 51.3 (CH2),
42.0 (CH3), 36.0 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3 (CH2), 27.3 (CH2), 23.9 (CH2), 22.9 (CH2), 22.0
(CH2), 13.9 (CH3); IR (ATR): νmax 3382, 2924, 2854, 2703, 1647, 1581, 1508, 1483, 1395, 1331, 1267, 1197,




The titled compound was synthesised from N-(3-(dimethylamino)propyl)-2-(4′-fluoro-4-
(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamide 11b (30 mg, 0.058 mmol) and 4 M HCl/dioxane
(0.10 mL, 0.40 mmol) following general synthetic procedure D. The product was obtained as a yellow
sticky solid (32 mg, 99%); 1H NMR (600 MHz, DMSO-d6): δ 10.43 (bs, 1H, NH), 10.18 (bs, 1H, NH),
9.02 (t, J = 6.0 Hz, NH), 8.00–7.95 (m, 2H, ArH), 7.73–7.68 (m, 2H, ArH), 7.60 (d, J = 9.0 Hz, 1H, ArH),
7.36–7.31 (m, 2H, ArH), 3.33-3.29 (m, 2H, CH2), 3.21 (t, J = 7.9 Hz, 2H, CH2), 3.12–3.07 (m, 2H, CH2),
2.73 (s, 6H, CH3), 1.98–1.90 (m, 2H, CH2), 1.70–1.63 (m, 2H, CH2), 1.37–1.15 (m, 10H, CH2), 0.82 (t,
J = 7.2 Hz, 3H, CH3); 13C NMR (150 MHz, DMSO-d6): δ 192.0 (CO), 163.7 (CO), 162.1 (ArC), 137.8
(ArC), 135.0 (ArC), 134.8 (ArC), 132.8 (ArCH), 130.1 (ArCH), 128.6 (ArCH), 126.1 (ArC), 122.5 (ArCH),
116.0 (ArCH), 54.4 (CH2), 51.3 (CH2), 42.0 (CH3), 42.0 (CH3), 36.0 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3
(CH2), 27.3 (CH2), 23.9 (CH2), 22.9 (CH2), 22.0 (CH2), 13.9 (CH3); IR (ATR): νmax 3358, 2925, 2855, 2690,
2360, 1647, 1603, 1515, 1488, 1400, 1332, 1222, 1196, 1143, 1099, 1012, 975, 919, 828, 725, 670, 597, 559,
520, 418 cm−1; HRMS (+ESI): Found m/z 520.2641 [M + H]+, C27H39FN3O4S required 520.2640.
3-(2-(4′-Chloro-4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamido)-N,N-dimethylpropan-
1-aminium chloride (13c)
The titled compound was synthesised from 2-(4′-chloro-4-(octylsulfonamido)-[1,1′-biphenyl]-3-
yl)-N-(3-(dimethylamino)propyl)-2-oxoacetamide 11c (30 mg, 0.056 mmol) and 4 M HCl/dioxane
(0.10 mL, 0.40 mmol) following general synthetic procedure D. The product was obtained as a yellow
sticky solid (29 mg, 92%); 1H NMR (600 MHz, DMSO-d6): δ 10.37 (bs, 1H, NH), 10.25 (bs, 1H, NH),
9.02 (t, J = 6.0 Hz, 1H, NH), 8.02–7.98 (m, 2H, ArH), 7.71–7.68 (m, 2H, ArH), 7.63–7.60 (m, 1H, ArH),
7.57–7.54 (m, 2H, ArH), 3.34–3.30 (m, 2H, CH2), 3.21 (t, J = 7.8 Hz, 2H, CH2), 3.12–3.07 (m, 2H, CH2),
2.73 (s, 6H, CH3), 1.98-1.90 (m, 2H, CH2), 1.70–1.63 (m, 2H, CH2), 1.36–1.15 (m, 10H, CH2), 0.82 (t,
J = 7.2 Hz, 3H, CH3); 13C NMR (150 MHz, DMSO-d6): δ 191.9 (CO), 163.6 (CO), 138.1 (ArC), 137.1
(ArC), 134.6 (ArC), 132.8 (ArC), 132.7 (ArCH), 130.2 (ArCH), 129.2 (ArCH), 128.3 (ArCH), 126.1 (ArC),
122.5 (ArCH), 54.4 (CH2), 51.4 (CH2), 42.1 (CH3), 36.0 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3 (CH2), 27.3
(CH2), 23.9 (CH2), 22.9 (CH2), 22.0 (CH2), 13.9 (CH3); IR (ATR): νmax 3372, 2924, 2854, 2704, 2359, 1643,
1578, 1507, 1481, 1400, 1333, 1273, 1196, 1143, 1092, 1012, 974, 918, 818, 758, 697, 668, 593, 511, 488 cm−1;
HRMS (+ ESI): Found m/z 536.2346 [M + H]+, C27H39ClN3O4S required 536.2344.
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N,N-Dimethyl-3-(2-(5-(naphthalen-2-yl)-2-(octylsulfonamido)phenyl)-2-oxoacetamido)propan-
1-aminium chloride (13d)
The titled compound was synthesised from N-(3-(dimethylamino)propyl)-2-(5-(naphthalen-2-yl)-
2-(octylsulfonamido)phenyl)-2-oxoacetamide 11d (32 mg, 0.058 mmol) and 4 M HCl/dioxane (0.10 mL,
0.40 mmol) following general synthetic procedure D. The product was obtained as a yellow sticky solid
(33 mg, 96%); 1H NMR (600 MHz, DMSO-d6): δ 10.26 (bs, 2H, NH), 9.03 (t, J = 5.9 Hz, 1H, NH), 8.23
(s, 1H, ArH), 8.16–8.13 (m, 2H, ArH), 8.06–8.01 (m, 2H, ArH), 7.96 (d, J = 7.6 Hz, 1H, ArH), 7.83 (dd,
J = 8.5, 1.4 Hz, 1H, ArH), 7.65 (d, J = 9.1 Hz, 1H, ArH), 7.60–7.52 (m, 2H, ArH), 3.35–3.29 (m, 2H, CH2),
3.22 (t, J = 7.7 Hz, 2H, CH2), 3.14–3.09 (m, 2H, CH2), 2.74 (s, 6H, CH3), 1.99-1.92 (m, 2H, CH2), 1.72–1.64
(m, 2H, CH2), 1.39–1.14 (m, 10H, CH2), 0.82 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (150 MHz, DMSO-d6): δ
192.0 (CO), 163.7 (CO), 137.8 (ArC), 135.9 (ArC), 135.6 (ArC), 133.2 (ArC), 133.0 (ArCH), 132.4 (ArC),
130.3 (ArCH), 128.7 (ArCH), 128.2 (ArCH), 127.5 (ArCH), 126.6 (ArCH), 126.6 (ArC), 126.4 (ArCH),
125.2 (ArCH), 124.6 (ArCH), 122.8 (ArCH), 54.5 (CH2), 51.3 (CH2), 42.0 (CH3), 36.0 (CH2), 31.1 (CH2),
28.4 (CH2), 28.3 (CH2), 27.3 (CH2), 23.9 (CH2), 22.9 (CH2), 22.0 (CH2), 13.9 (CH3); IR (ATR): νmax 3675,
2924, 2854, 2698, 1641, 1494, 1466, 1397, 1331, 1269, 1236, 1201, 1143, 1086, 919, 892, 861, 815, 747, 720,
670, 557, 516, 476 cm−1; HRMS (+ ESI): Found m/z 552.2893 [M + H]+, C31H42N3O4S required 552.2891.
3-(2-(5-Butyl-2-(octylsulfonamido)phenyl)-2-oxoacetamido)-N,N-dimethylpropan-1-aminium
chloride (13e)
The titled compound was synthesised from 2-(5-butyl-2-(octylsulfonamido)phenyl)-N-(3-
(dimethylamino)propyl)-2-oxoacetamide 11e (33 mg, 0.069 mmol) and 4 M HCl/dioxane (0.10 mL,
0.40 mmol) following general synthetic procedure D. The product was obtained as a yellow sticky
solid (35 mg, 99%); 1H NMR (600 MHz, DMSO-d6): δ 10.29 (bs, 1H, NH), 10.04 (bs, 1H, NH), 8.92 (t,
J = 6.0 Hz, 1H, NH), 7.54–7.50 (m, 2H, ArH), 7.41 (dd, J = 7.7, 0.9 Hz, 1H, ArH), 3.32–3.27 (m, 2H,
CH2), 3.15–3.06 (m, 4H, CH2), 2.74 (s, 6H, CH3), 2.61 (t, J = 7.8 Hz, 2H, CH2), 1.96–1.89 (m, 2H, CH2),
1.66–1.50 (m, 4H, CH2), 1.34–1.15 (m, 12H, CH2), 0.89 (t, J = 7.3 Hz, 3H, CH3), 0.84 (t, J = 7.3 Hz, 3H,
CH3); 13C NMR (150 MHz, DMSO-d6): δ 192.6 (CO), 164.2 (CO), 138.6 (ArC), 136.4 (ArC), 134.8 (ArCH),
131.7 (ArCH), 125.6 (ArCH), 122.0 (ArCH), 54.5 (CH2), 51.0 (CH2), 42.1 (CH3), 35.9 (CH2), 33.8 (CH2),
32.9 (CH2), 31.1 (CH2), 28.3 (CH2), 28.3 (CH2), 27.3 (CH2), 23.9 (CH2), 22.9 (CH2), 22.0 (CH2), 32.7
(CH2), 13.9 (CH3), 13.7 (CH3); IR (ATR): νmax 3379, 2953, 2922, 2855, 2674, 2360, 1670, 1578, 1524, 1496,
1465, 1443, 1400, 1334, 1253, 1179, 1153, 1086, 978, 918, 906, 874, 836, 799, 759, 677, 604, 570, 544, 516,
475, 432 cm−1; HRMS (+ ESI): Found m/z 482.3046 [M + H]+, C25H44N3O4S required 482.3047.
3-(2-(4-(Butylsulfonamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamido)-N,N-dimethylpropan-1-aminium
chloride (14a)
The titled compound was synthesised from 2-(4-(butylsulfonamido)-[1,1′-biphenyl]-3-yl)-N-(3-
(dimethylamino)propyl)-2-oxoacetamide 12a (35 mg, 0.079 mmol) and 4 M HCl/dioxane (0.10 mL,
0.40 mmol) following general synthetic procedure D. The product was obtained as a yellow sticky
solid (34 mg, 91%); 1H NMR (600 MHz, DMSO-d6): δ 10.30 (bs, 1H, NH), 10.18 (bs, 1h, NH), 9.03 (t,
J = 6.0 Hz, 1H, NH), 8.01–7.98 (m, 2H, ArH), 7.67–7.64 (m, 2H, ArH), 7.63–7.60 (m, 1H, ArH), 7.52–7.48
(m, 2H, ArH), 7.42–7.38 (m, 1H, ArH), 3.34–3.30 (m, 2H, CH2), 3.24–3.20 (m, 2H, CH2), 3.13–3.07 (m,
2H, CH2), 2.74 (s, 6H, CH3), 1.97–1.91 (m, 2H, CH2), 1.70–1.63 (m, 2H, CH2), 1.41–1.33 (m, 2H, CH2),
0.85 (t, J = 7.5 Hz, 3H, CH3); 13C NMR (150 MHz, DMSO-d6): δ 192.1 (CO), 163.8 (CO), 138.3 (ArC),
137.8 (ArC), 136.0 (ArC), 132.9 (ArCH), 130.2 (ArCH), 129.2 (ArCH), 127.9 (ArCH), 126.5 (ArCH), 125.9
(ArC), 122.4 (ArCH), 54.5 (CH2), 51.1 (CH2), 42.1 (CH3), 36.0 (CH2), 24.9 (CH2), 23.9 (CH2), 20.7 (CH2),
13.4 (CH3); IR (ATR): νmax 3363, 2960, 2872, 2690, 2361, 1643, 1581, 1508, 1483, 1394, 1330, 1266, 1239,
1196, 1144, 1076, 974, 921, 843, 800, 761, 698, 681, 616, 585, 539 cm−1; HRMS (+ ESI): Found m/z 446.2109
[M + H] +, C23H32N3O4S required 446.2108.
Int. J. Mol. Sci. 2020, 21, 6789 23 of 38
General Synthetic Procedure E for Quaternary Ammonium Iodide Salts
To a solution of glyoxamide derivative (1.0 equivalent) in THF (5 mL), iodomethane (2.5 equivalents)
was added. The reaction mixture was stirred at room temperature for 24 h. After completion of reaction,




The titled compound was synthesised from N-(3-(Dimethylamino)propyl)-2-(4-(octylsulfonamido)-
[1,1′-biphenyl]-3-yl)-2-oxoacetamide 11a (33 mg, 0.066 mmol) and iodomethane (10 µL, 0.17 mmol)
following general synthetic procedure E. The product was obtained as a yellow sticky solid (40 mg,
94%); 1H NMR (600 MHz, DMSO-d6): δ 10.10 (bs, 1H, NH), 8.98 (t, J = 5.9 Hz, 1H, NH), 8.03–7.97
(m, 2H, ArH), 7.68–7.64 (m, 2H, ArH), 7.59–7.56 (m, 1H, ArH), 7.52–7.48 (m, 2H, ArH), 7.43–7.39 (m,
1H, ArH), 3.39–3.30 (m, 4H, CH2), 3.21–3.16 (m, 2H, CH2), 3.06 (s, 9H, CH2), 2.02–1.95 (m, 2H, CH2),
1.70–1.63 (m, 2H, CH2), 1.39–1.15 (m, 10H, CH3), 0.83 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (150 MHz,
DMSO-d6): δ 191.8 (CO), 163.7 (CO), 138.3 (ArC), 132.7 (ArCH), 130.1 (ArCH), 129.2 (ArC), 129.2
(ArCH), 128.0 (ArCH), 126.8 (ArC), 126.5 (ArCH), 126.2 (ArC), 122.9 (ArCH), 63.5 (CH2), 52.3 (CH3),
51.2 (CH2), 35.9 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3 (CH2), 27.3 (CH2), 22.9 (CH2), 22.6 (CH2), 22.0
(CH2), 13.9 (CH3); IR (ATR): νmax 3396, 3032, 2925, 2854, 1647, 1582, 1508, 1483, 1394, 1330, 1265, 1195,




The titled compound was synthesised from N-(3-(dimethylamino)propyl)-2-(4′-fluoro-4-
(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamide 11b (32 mg, 0.062 mmol) and iodomethane
(10 µL, 0.16 mmol) following general synthetic procedure E. The product was obtained as a yellow
sticky solid (39 mg, 95%); 1H NMR (600 MHz, DMSO-d6): δ 10.07 (bs, 1H, NH), 8.97 (t, J = 6.0 Hz,
1H, NH), 7.99–7.94 (m, 2H, ArH), 7.73–7.69 (m, 2H, ArH), 7.56 (d, J = 8.1 Hz, 1H, ArH), 7.35–7.30 (m,
2H, ArH), 3.39–3.30 (m, 4H, CH2), 3.17 (t, J = 7.8 Hz, 2H, CH2), 3.07 (s, 9H, CH3), 2.02–1.95 (m, 2H,
CH2), 1.71–1.62 (m, 2H, CH2), 1.39–1.14 (m, 10H, CH2), 0.82 (t, J = 7.2 Hz, 3H, CH3); 13C NMR (150
MHz, DMSO-d6): δ 191.7 (CO), 163.6 (CO), 162.1 (ArC), 137.4 (ArC), 135.3 (ArC), 134.8 (ArC), 132.6
(ArCH), 130.0 (ArCH), 128.6 (ArCH), 127.2 (ArC), 123.1 (ArCH), 116.0 (ArCH), 63.5 (CH2), 52.3 (CH3),
51.2 (CH2), 35.9 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3 (CH2), 27.3 (CH2), 22.9 (CH2), 22.6 (CH2), 22.0
(CH2), 13.9 (CH3); IR (ATR): νmax 3410, 2925, 2855, 2359, 1647, 1603, 1516, 1488, 1400, 1331, 1262, 1221,




The titled compound was synthesised from 2-(4′-chloro-4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-
N-(3-(dimethylamino)propyl)-2-oxoacetamide 11c (35 mg, 0.065 mmol) and iodomethane (10 µL,
0.16 mmol) following general synthetic procedure E. The product was obtained as a yellow sticky solid
(41 mg, 93%); 1H NMR (600 MHz, DMSO-d6): δ 10.09 (bs, 1H, NH), 8.97 (bs, 1H, NH), 8.03-7.96 (m, 2H,
ArH), 7.72-7.67 (m, 2H, ArH), 7.60-7.53 (m, 3H, ArH), 3.39–3.30 (m, 4H, CH2), 3.17 (t, J = 7.7 Hz, 2H,
CH2), 3.07 (s, 9H, CH3), 2.02–1.95 (m, 2H, CH2), 1.70–1.63 (m, 2H, CH2), 1.38–1.14 (m, 10H, CH2), 0.82
(t, J = 7.2 Hz, 3H, CH3); 13C NMR (150 MHz, DMSO-d6): δ 191.6 (CO), 163.6 (CO), 137.1 (ArC), 132.8
(ArC), 132.6 (ArCH), 130.0 (ArCH), 129.2 (ArC), 129.1 (ArCH), 128.3 (ArCH), 128.0 (ArC), 127.1 (ArC),
123.1 (ArCH), 63.5 (CH2), 52.3 (CH3), 51.2 (CH2), 35.9 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3 (CH2), 27.3
(CH2), 22.9 (CH2), 22.6 (CH2), 22.0 (CH2), 13.9 (CH3); IR (ATR): νmax 3854, 3807, 3691, 3650, 3629, 2924,
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2854, 2360, 1978, 1654, 1648, 1578, 1560, 1508, 1481, 1400, 1330, 1274, 1195, 1141, 1092, 1012, 915, 818,




The titled compound was synthesised from N-(3-(dimethylamino)propyl)- 2-(5-(naphthalen-2
-yl)-2-(octylsulfonamido)phenyl)-2-oxoacetamide 11d (35 mg, 0.063 mmol) and iodomethane (10 µL,
0.16 mmol) following general synthetic procedure E. The product was obtained as a yellow sticky solid
(40 mg, 90%); 1H NMR (600 MHz, DMSO-d6): δ 10.12 (bs, 1H, NH), 9.00 (t, J = 6.1 Hz, 1H, NH), 8.24 (d,
J = 1.5 Hz, 1H, ArH), 8.17–8.13 (m, 2H, ArH), 8.06–8.00 (m, 2H, ArH), 7.98–7.95 (m, 1H, ArH), 7.84
(dd, J = 8.5, 1.9 Hz, 1H, ArH), 7.62 (d, J = 8.4 Hz, 1H, ArH), 7.59–7.54 (m, 2H, ArH), 3.41–3.33 (m, 4H,
CH2), 3.19 (t, J = 7.7 Hz, 2H, CH2), 3.07 (s, 9H, CH3), 2.03–1.97 (m, 2H, CH2), 1.72–1.65 (m, 2H, CH2),
1.38–1.30 (m, 2H, CH2), 1.26–1.15 (m, 8H, CH2), 0.82 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (150 MHz,
DMSO-d6): δ 191.7 (CO), 163.7 (CO), 137.4 (ArC), 136.3 (ArC), 135.6 (ArC), 133.2 (ArC), 132.9 (ArCH),
132.4 (ArC), 130.2 (ArCH), 128.8 (ArCH), 128.2 (ArCH), 127.6 (ArCH), 127.5 (ArC), 126.7 (ArCH), 126.5
(ArCH), 125.3 (ArCH), 124.7 (ArCH), 123.3 (ArCH), 63.5 (CH2), 52.3 (CH3), 51.2 (CH2), 35.9 (CH2), 31.1
(CH2), 28.4 (CH2), 28.3 (CH2), 27.3 (CH2), 22.9 (CH2), 22.6 (CH2), 22.0 (CH2), 13.9 (CH3); IR (ATR):
νmax 3422, 3051, 2924, 2853, 2360, 1642, 1492, 1466, 1396, 1329, 1263, 1234, 1202, 1189, 1142, 1088, 915,




The titled compound was synthesised from 2-(5-butyl-2-(octylsulfonamido)phenyl)-N-(3-
(dimethylamino)propyl)-2-oxoacetamide 11e (32 mg, 0.066 mmol) and iodomethane (10 µL, 0.17 mmol)
following general synthetic procedure E. The product was obtained as a yellow sticky solid (35 mg,
85%); 1H NMR (600 MHz, DMSO-d6): δ 9.95 (bs, 1H, NH), 8.88 (t, J = 6.0 Hz, 1H, NH), 7.55–7.51 (m, 2H,
ArH), 7.40–7.36 (m, 1H, ArH), 3.40–3.27 (m, 4H, CH2), 3.12–3.05 (m, 11H, CH2, CH3), 2.61 (t, J = 7.6 Hz,
2H, CH2), 2.01–1.94 (m, 2H, CH2), 1.66–1.59 (m, 2H, CH2), 1.58–1.50 (m, 2H, CH2), 1.35–1.15 (m, 12H,
CH2), 0.89 (t, J = 7.5 Hz, 3H, CH3), 0.84 (t, J = 7.3 Hz, 3H, CH3); 13C NMR (150 MHz, DMSO-d6): δ 192.3
(CO), 164.1 (CO), 139.1 (ArC), 135.9 (ArC), 134.6 (ArCH), 131.5 (ArCH), 126.9 (ArC), 122.7 (ArCH), 63.5
(CH2), 52.3 (CH3), 50.9 (CH2), 35.8 (CH2), 33.8 (CH2), 32.9 (CH2), 31.1 (CH2), 28.3 (CH2), 28.3 (CH2),
27.3 (CH2), 22.9 (CH2), 22.6 (CH2), 22.0 (CH2), 21.7 (CH2), 13.9 (CH3), 13.7 (CH3); IR (ATR): νmax 3424,
2954, 2925, 2855, 2358, 1670, 1577, 1529, 1492, 1466, 1397, 1328, 1233, 1178, 1141, 1074, 914, 837, 775, 723,
668, 553, 509, 424 cm−1; HRMS (+ ESI): Found m/z 496.3202 [M] +, C26H44N3O4S required 496.3204.
3-(2-(4-(Butylsulfonamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamido)-N,N,N-trimethylpropan-1-aminium
iodide (16a)
The titled compound was synthesised from 2-(4-(butylsulfonamido)-[1,1′-biphenyl]-3-yl)-N-
(3-(dimethylamino)propyl)-2-oxoacetamide 12a (34 mg, 0.076 mmol) and iodomethane (12 µL,
0.19 mmol) following general synthetic procedure E. The product was obtained as a yellow sticky
solid (26 mg, 58%); 1H NMR (600 MHz, DMSO-d6): δ 10.08 (bs, 1H, NH), 8.98 (t, J = 5.8 Hz, 1H,
NH), 8.02–7.98 (m, 2H, ArH), 7.68–7.64 (m, 2H, ArH), 7.60–7.56 (m, 1H, ArH), 7.52–7.47 (m, 2H, ArH),
7.43–7.39 (m, 1H, ArH), 3.39–3.30 (m, 4H, CH2), 3.21–3.16 (m, 2H, CH2), 3.07 (s, 9H, CH2), 2.02–1.95 (m,
2H, CH2), 1.70–1.63 (m, 2H, CH2), 1.41–1.33 (m, 2H, CH3), 0.85 (t, J = 7.4 Hz, 3H, CH3); 13C NMR (150
MHz, DMSO-d6): δ 191.8 (CO), 163.7 (CO), 138.3 (ArC), 132.7 (ArCH), 130.1 (ArCH), 129.2 (ArC), 129.2
(ArCH), 127.9 (ArCH), 126.9 (ArC), 126.5 (ArCH), 126.3 (ArC), 123.0 (ArCH), 63.5 (CH2), 52.3 (CH3),
51.0 (CH2), 35.9 (CH2), 25.0 (CH2), 22.6 (CH2), 20.7 (CH2), 13.5 (CH3); IR (ATR): νmax 3195, 3032, 2959,
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2872, 2359, 1979, 1644, 1582, 1508, 1482, 1452, 1394, 1329, 1268, 1195, 1140, 1076, 920, 842, 762, 699, 681,
616, 584, 536, 428 cm−1; HRMS (+ ESI): Found m/z 460.2264 [M] +, C24H34N3O4S required 460.2265.
General Synthetic Procedure F for Boc-Protected Glyoxamide Derivatives
To a solution of N-sulfonylisatin (1.0 equivalent) in dichloromethane (10 mL), N-Boc-1,
3-propandiamine (1.0 equivalent) in dichloromethane (5 mL) was added dropwise with stirring
at 0 ◦C. The reaction mixture was stirred at room temperature for 6 h. After completion of the
reaction, water was added to the reaction mixture and the product was extracted into dichloromethane
(3 × 30 mL), washed with brine, dried over anhydrous sodium sulphate and concentrated in vacuo to
afford the product.
tert-Butyl (3-(2-(4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamido)propyl)carbamate (18a)
The titled compound was synthesised from 1-(octylsulfonyl)-5-phenylindoline-2,3-dione 8a (0.32 g,
0.81 mmol) and N-Boc-1,3-propandiamine (0.15 g, 0.82 mmol) following general synthetic procedure
F. The product was obtained as a yellow solid (0.45 g, 97%); mp 127.3–127.4 ◦C; 1H NMR (600 MHz,
CDCl3): δ 10.48 (bs, 1H, NH), 8.75 (s, 1H, ArH), 7.88–7.81 (m, 2H, ArH), 7.71 (bs, 1H, NH), 7.59–7.55
(m, 2H, ArH), 7.47–7.43 (m, 2H, ArH), 7.39–7.35 (m, 1H, ArH), 4.81 (bs, 1H, NH), 3.48 (q, J = 6.4 Hz, 2H,
CH2), 3.27–3.21 (m, 2H, CH2), 3.21–3.16 (m, 2H, CH2), 1.85–1.78 (m, 2H, CH2), 1.78–1.73 (m, 2H, CH2),
1.44 (s, 9H, CH3), 1.42–1.34 (m, 2H, CH2), 1.30–1.16 (m, 8H, CH2), 0.85 (t, J = 7.2 Hz, 3H, CH3); 13C
NMR (150 MHz, CDCl3): δ 191.5 (CO), 162.9 (CO), 156.9 (CO), 141.1 (ArC), 139.1 (ArC), 135.7 (ArC),
135.1 (ArCH), 133.7 (ArCH), 129.2 (ArCH), 127.9 (ArCH), 126.9 (ArCH), 119.3 (ArC), 118.5 (ArCH),
79.9 (C), 52.8 (CH2), 37.3 (CH2), 36.4 (CH2), 31.8 (CH2), 30.2 (CH2), 29.1 (CH2), 29.0 (CH2), 28.5 (CH3),
28.2 (CH2), 23.5 (CH2), 22.7 (CH2), 14.2 (CH3); IR (ATR): νmax 3352, 3310, 2919, 2359, 1682, 1666, 1582,
1518, 1483, 1443, 1386, 1364, 1346, 1325, 1294, 1246, 1197, 1171, 1155, 1124, 1069, 1041, 1011, 977, 968,
906, 894, 851, 830, 804, 760, 741, 714, 684, 639, 609, 554, 537, 491, 453, 423 cm−1; HRMS (+ ESI): Found
m/z 596.2764 [M + Na] +, C30H43N3O6SNa required 596.2764.
tert-Butyl (3-(2-(4′-fluoro-4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamido)propyl)
carbamate (18b)
The titled compound was synthesised from 5-(4-fluorophenyl)-1-(octylsulfonyl)indoline-2,3-dione
8b (0.28 g, 0.67 mmol) and N-Boc-1,3-propandiamine (0.12 g, 0.67 mmol) following general synthetic
procedure F. The product was obtained as a yellow solid (0.38 g, 96%); mp 138.0–140.3 ◦C; 1H NMR
(400 MHz, CDCl3): δ 10.46 (bs, 1H, NH), 8.72 (s, 1H, ArH), 7.85 (d, J = 8.7 Hz, 1H, ArH), 7.81–7.69
(m, 2H, NH, ArH), 7.56–7.50 (m, 2H, ArH), 7.17–7.09 (m, 2H, ArH), 4.81 (t, J = 5.9 Hz, 1H, NH), 3.47
(q, J = 6.4 Hz, 2H, CH2), 3.29–3.14 (m, 4H, CH2), 1.86–1.71 (m, 4H, CH2), 1.44 (s, 9H, CH3), 1.42–1.33
(m, 2H, CH2), 1.31–1.18 (m, 8H, CH2), 0.85 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3): δ
191.3 (CO), 162.8 (CO), 162.8 (ArC), 156.9 (CO), 141.1 (ArC), 135.2 (ArC), 134.9 (ArCH), 134.7 (ArC),
133.5 (ArCH), 128.6 (ArCH), 119.3 (ArC), 118.6 (ArCH), 116.1 (ArCH), 79.9 (C), 52.8 (CH2), 37.3 (CH2),
36.4 (CH2), 31.8 (CH2), 30.2 (CH2), 29.1 (CH2), 29.0 (CH2), 28.5 (CH3), 28.2 (CH2), 23.5 (CH2), 22.7
(CH2), 14.2 (CH3); IR (ATR): νmax 3357, 3313, 2923, 2856, 2303, 1887, 1680, 1645, 1519, 1487, 1388, 1344,




The titled compound was synthesised from 5-(4-chlorophenyl)-1-(octylsulfonyl)indoline-2,3-dione
8c (0.30 g, 0.69 mmol) and N-Boc-1,3-propandiamine (0.13 g, 0.71 mmol) following general synthetic
procedure F. The product was obtained as a yellow solid (0.41 g, 97%); mp 134.7–135.1 ◦C; 1H NMR
(600 MHz, CDCl3): δ 10.49 (bs, 1H, NH), 8.74 (s, 1H, ArH), 7.85 (d, J = 8.7 Hz, 1H, ArH), 7.78 (dd,
J = 8.7, 2.3 Hz, 1H, ArH), 7.77 (bs, 1H, NH), 7.51–7.48 (m, 2H, ArH), 7.43–7.40 (m, 2H, ArH), 4.81 (bs,
Int. J. Mol. Sci. 2020, 21, 6789 26 of 38
1H, NH), 3.47 (q, J = 6.4 Hz, 2H, CH2), 3.27–3.22 (m, 2H, CH2), 3.20–3.16 (m, 2H, CH2), 1.84–1.72 (m,
4H, CH2), 1.44 (s, 9H, CH3), 1.41–1.34 (m, 2H, CH2), 1.29–1.18 (m, 8H, CH2), 0.85 (t, J = 7.2 Hz, 3H,
CH3); 13C NMR (150 MHz, CDCl3): δ 191.3 (CO), 162.7 (CO), 156.9 (CO), 141.3 (ArC), 137.5 (ArC),
134.8 (ArCH), 134.4 (ArC), 134.1 (ArC), 133.5 (ArCH), 129.3 (ArCH), 128.2 (ArCH), 119.3 (ArC), 118.6
(ArCH), 79.9 (C), 52.8 (CH2), 37.3 (CH2), 36.4 (CH2), 31.8 (CH2), 30.2 (CH2), 29.1 (CH2), 29.0 (CH2),
28.5 (CH3), 28.2 (CH2), 23.5 (CH2), 22.7 (CH2), 14.2 (CH3); IR (ATR): νmax 3352, 3311, 2922, 2855, 2359,
1979, 1682, 1665, 1643, 1581, 1519, 1483, 1443, 1388, 1364, 1345, 1246, 1197, 1155, 1138, 1093, 1070, 1041,
1010, 975, 907, 895, 882, 864, 817, 759, 741, 714, 685, 643, 609, 555, 537, 492, 471, 418 cm−1; HRMS (+ ESI):
Found m/z 630.2379 [M + Na] +, C30H42ClN3O6SNa required 630.2375.
tert-Butyl (3-(2-(5-(naphthalen-2-yl)-2-(octylsulfonamido)phenyl)-2-oxoacetamido)propyl)
carbamate (18d)
The titled compound was synthesised from 5-(naphthalen-2-yl)-1-(octylsulfonyl)indoline-2,3-dione
8d (0.31 g, 0.70 mmol) and N-Boc-1,3-propandiamine (0.13 g, 0.70 mmol) following general synthetic
procedure F. The product was obtained as a yellow solid (0.41 g, 95%); mp 78.9–80.0 ◦C; 1H NMR
(600 MHz, CDCl3): δ 10.51 (bs, 1H, NH), 8.87 (s, 1H, ArH), 8.01 (s, 1H, ArH), 7.99–7.83 (m, 5H, ArH),
7.79–7.67 (m, 2H, NH, ArH), 7.55–7.46 (m, 2H, ArH), 4.84 (bs, 1H, NH), 3.49 (q, J = 6.5 Hz, 2H, CH2),
3.30–3.16 (m, 4H, CH2), 1.88–1.72 (m, 4H, CH2), 1.44 (s, 9H, CH3), 1.46–1.34 (m, 2H, CH2), 1.31–1.16 (m,
8H, CH2), 0.85 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (150 MHz, CDCl3): δ 191.5 (CO), 162.9 (CO), 156.9
(CO), 141.1 (ArC), 136.3 (ArC), 135.6 (ArC), 135.4 (ArCH), 133.8 (ArCH), 133.7 (ArC), 132.9 (ArC), 128.9
(ArCH), 128.4 (ArCH), 127.8 (ArCH), 126.7 (ArCH), 126.4 (ArCH), 125.7 (ArCH), 125.0 (ArCH), 119.4
(ArC), 118.6 (ArCH), 79.9 (C), 52.8 (CH2), 37.3 (CH2), 36.5 (CH2), 31.8 (CH2), 30.2 (CH2), 29.1 (CH2),
29.0 (CH2), 28.5 (CH3), 28.2 (CH2), 23.6 (CH2), 22.7 (CH2), 14.2 (CH3); IR (ATR): νmax 3346, 3055, 2925,
2855, 2285, 2081, 1911, 1683, 1636, 1572, 1497, 1466, 1393, 1365, 1336, 1247, 1140, 1012, 917, 890, 813,
747 cm−1; HRMS (+ ESI): Found m/z 646.2919 [M + Na] +, C34H45N3O6SNa required 646.2921.
General Synthetic Procedure G for Aminoglyoxamides
To a solution of Boc-protected glyoxamide (1.0 equivalent) in dichloromethane (10 mL), 4 M
HCl/dioxane (3 mL) was added. The reaction mixture was stirred at room temperature for 6 h.
After completion of reaction, the reaction mixture was concentrated in vacuo, washed thrice with
diethyl ether and dried under high vacuum to afford the product.
N-(3-Aminopropyl)-2-(4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamide hydrochloride (19a)
The titled compound was synthesised from tert-butyl (3-(2-(4-(octylsulfonamido)-[1,1′-biphenyl]-3
-yl)-2-oxoacetamido)propyl)carbamate 18a (0.35 g, 0.61 mmol) following general synthetic procedure
G. The product was obtained as a yellow solid (0.20 g, 64%); mp 126.2–128.7 ◦C; 1H NMR (400 MHz,
DMSO-d6): δ 10.20 (bs, 1H, NH), 9.05 (t, J = 6.0 Hz, 1H, NH), 8.19–7.91 (m, 5H, NH, ArH), 7.66–7.61 (m,
3H, ArH), 7.51 (t, J = 7.8 Hz, 2H, ArH), 7.41 (t, J = 7.2 Hz, 1H, ArH), 3.38–3.29 (m, 2H, CH2), 3.29–3.22
(m, 2H, CH2), 2.91–2.82 (m, 2H, CH2), 1.89–1.79 (m, 2H, CH2), 1.72–1.62 (m, 2H, CH2), 1.39–1.14 (m,
10H, CH2), 0.82 (t, J = 7.0 Hz, 3H, CH3); 13C NMR (100 MHz, DMSO-d6): δ 192.4 (CO), 163.8 (CO),
138.3 (ArC), 138.2 (ArC), 135.6 (ArC), 133.2 (ArCH), 130.5 (ArCH), 129.2 (ArCH), 127.9 (ArCH), 126.4
(ArCH), 124.5 (ArC), 121.7 (ArCH), 51.4 (CH2), 36.7 (CH2), 35.9 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3
(CH2), 27.3 (CH2), 26.9 (CH2), 22.9 (CH2), 22.0 (CH2), 14.2 (CH3); IR (ATR): νmax 3031, 2921, 2853, 2045,
1961, 1635, 1509, 1482, 1393, 1335, 1264, 1196, 1138, 1025, 917, 838, 759, 696 cm−1; HRMS (+ ESI): Found
m/z 474.2419 [M + H] +, C25H36N3O4S required 474.2421.
N-(3-Aminopropyl)-2-(4′-fluoro-4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamide
hydrochloride (19b)
The titled compound was synthesised from tert-butyl (3-(2-(4′-fluoro-4-(octylsulfonamido)-[1,
1′-biphenyl]-3-yl)-2-oxoacetamido)propyl) carbamate 18b (0.34 g, 0.58 mmol) following general
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synthetic procedure G. The product was obtained as a yellow solid (0.27 g, 90%); mp 155.2–157.8 ◦C;
1H NMR (400 MHz, DMSO-d6): δ 10.19 (bs, 1H, NH), 9.05 (t, J = 5.9 Hz, 1H, NH), 8.14–7.93 (m, 5H,
NH, ArH), 7.72–7.65 (m, 2H, ArH), 7.65–7.59 (m, 1H, ArH), 7.34 (t, J = 8.9 Hz, 2H, ArH), 3.37–3.29
(m, 2H, CH2), 3.28–3.21 (m, 2H, CH2), 2.92–2.80 (m, 2H, CH2), 1.90–1.79 (m, 2H, CH2), 1.72–1.61 (m,
2H, CH2), 1.38–1.14 (m, 10H, CH2), 0.82 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (100 MHz, DMSO-d6): δ
192.3 (CO), 163.7 (CO), 162.1 (ArC), 138.2 (ArC), 134.7 (ArC), 134.6 (ArC), 133.0 (ArCH), 130.3 (ArCH),
128.5 (ArCH), 124.7 (ArC), 121.8 (ArCH), 116.0 (ArCH), 51.4 (CH2), 36.6 (CH2), 35.9 (CH2), 31.1 (CH2),
28.3 (CH2), 28.3 (CH2), 27.3 (CH2), 26.9 (CH2), 22.9 (CH2), 22.0 (CH2), 13.9 (CH3); IR (ATR): νmax 3365,
3161, 2970, 2925, 2753, 2611, 2494, 2343, 2058, 1919, 1633, 1600, 1528, 1491, 1393, 1334, 1259, 1203, 1140,




The titled compound was synthesised from tert-butyl (3-(2-(4′-chloro-4-(octylsulfonamido)-[1,
1′-biphenyl]-3-yl)-2-oxoacetamido)propyl) carbamate 18c (0.38 g, 0.62 mmol) following general
synthetic procedure G. The product was obtained as a yellow solid (0.28 g, 83%); mp 118.8–119.1 ◦C;
1H NMR (400 MHz, DMSO-d6): δ 10.19 (bs, 1H, NH), 9.04 (t, J = 6.0 Hz, 1H, NH), 8.12–7.88 (m, 5H,
NH, ArH), 7.71–7.60 (m, 3H, ArH), 7.57 (d, J = 8.5 Hz, 2H, ArH), 3.38–3.29 (m, 2H, CH2), 3.28–3.21 (m,
2H, CH2), 2.92–2.81 (m, 2H, CH2), 1.89–1.79 (m, 2H, CH2), 1.72–1.61 (m, 2H, CH2), 1.39–1.13 (m, 10H,
CH2), 0.82 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (100 MHz, DMSO-d6): δ 192.2 (CO), 163.7 (CO), 138.4
(ArC), 137.0 (ArC), 134.3 (ArC), 133.0 (ArCH), 132.8 (ArC), 130.4 (ArCH), 129.2 (ArCH), 128.3 (ArCH),
124.8 (ArC), 121.9 (ArCH), 51.5 (CH2), 36.7 (CH2), 35.9 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3 (CH2), 27.3
(CH2), 26.9 (CH2), 22.9 (CH2), 22.0 (CH2), 13.9 (CH3); IR (ATR): νmax 3808, 2924, 2855, 2360, 2038, 1657,
1636, 1578, 1527, 1509, 1483, 1397, 1340, 1270, 1201, 1139, 1095, 1046, 1010, 919, 875, 815, 772, 700, 668,
596, 562, 494 cm−1; HRMS (+ ESI): Found m/z 508.2033 [M + H] +, C25H35ClN3O4S required 508.2031.
N-(3-Aminopropyl)-2-(5-(naphthalen-2-yl)-2-(octylsulfonamido)phenyl)-2-oxoacetamide
hydrochloride (19d)
The titled compound was synthesised from tert-Butyl (3-(2-(5-(naphthalen-2-yl)-2-(octylsulfonamido)
phenyl)-2-oxoacetamido)propyl) carbamate 18d (0.37 g, 0.59 mmol) following general synthetic
procedure G. The product was obtained as a yellow solid (0.22 g, 67%); mp 85.2–87.3 ◦C; 1H NMR
(400 MHz, DMSO-d6): δ 10.23 (bs, 1H, NH), 9.07 (t, J = 5.9 Hz, 1H, NH), 8.22 (s, 1H, ArH), 8.18–8.12 (m,
2H, ArH), 8.10–7.93 (m, 6H, NH, ArH), 7.81 (dd, J = 8.6, 1.8 Hz, 1H, ArH), 7.68 (dd, J = 6.4, 2.8 Hz,
1H, ArH),7.60–7.52 (m, 2H, ArH), 3.40–3.31 (m, 2H, CH2), 3.29–3.22 (m, 2H, CH2), 2.92–2.82 (m, 2H,
CH2), 1.92–1.82 (m, 2H, CH2), 1.74–1.63 (m, 2H, CH2), 1.39–1.14 (m, 10H, CH2), 0.81 (t, J = 7.0 Hz, 3H,
CH3); 13C NMR (100 MHz, DMSO-d6): δ 192.3 (CO), 163.8 (CO), 138.2 (ArC), 135.6 (ArC), 133.2 (ArC),
133.2 (ArCH), 132.3 (ArC), 130.6 (ArCH), 128.9 (ArCH), 128.3 (ArCH), 127.6 (ArC), 127.6 (ArCH),
126.6 (ArCH), 126.4 (ArCH), 125.2 (ArC), 125.2 (ArCH), 124.6 (ArCH), 122.1 (ArCH), 51.4 (CH2), 36.7
(CH2), 35.9 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3 (CH2), 27.3 (CH2), 26.9 (CH2), 22.9 (CH2), 22.0 (CH2),
13.9 (CH3); IR (ATR): νmax3312, 3176, 2921, 2852, 2321, 2050, 1922, 1635, 1494, 1463, 1396, 1333, 1264,
1200, 1138, 1016, 916, 812, 747 cm−1; HRMS ( + ESI): Found m/z 524.2579 [M + H] +, C29H38N3O4S
required 524.2578.
General Synthetic Procedure H for Boc-Protected Guanidine Glyoxamides
To a solution of aminoglyoxamides (1.0 equivalent) and N,N′-di-Boc-1H-pyrazole-1- carboxamidine
(1.3 equivalents) in acetonitrile (10 mL), triethylamine (2.5 equivalents) in acetonitrile (5 mL) was
added dropwise with stirring at 0 ◦C under nitrogen atmosphere. The reaction mixture was stirred at
room temperature for 18 h. After completion of the reaction, the reaction mixture was concentrated in
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vacuo. The product was purified by flash chromatography on silica using ethyl acetate/n-hexane (1:4)
as eluent to afford the product.
(E)-1-tert-Butyl-N-(N′-((tert-butyloxidanyl)carbonyl)-N-(3-(2-(4-(octylsulfonamido)-[1,1′-biphenyl]-
3-yl)-2-oxoacetamido)propyl)carbamimidoyl)-1-oxidanecarboxamide (21a)
The titled compound was synthesised from N-(3-aminopropyl)-2-(4-(octylsulfonamido)-[1,
1′-biphenyl]-3-yl)-2-oxoacetamide hydrochloride 19a (0.16 g, 0.30 mmol), N,N′-di-Boc-1H-pyrazole-1
-carboxamidine (0.14 g, 0.45 mmol) and triethylamine (0.12 mL, 0.83 mmol) following general synthetic
procedure H. The product was obtained as a yellow solid (68 mg, 31%); mp 69.9–70.1 ◦C; 1H NMR
(400 MHz, CDCl3): δ 11.47 (bs, 1H, NH), 10.62 (bs, 1H, NH), 8.68–8.50 (m, 3H, NH, ArH), 7.89–7.80
(m, 2H, ArH), 7.57 (d, J = 7.5 Hz, 2H, ArH), 7.45 (t, J = 7.9 Hz, 2H, ArH), 7.36 (t, J = 7.1 Hz, 1H, ArH),
3.62–3.52 (m, 2H, CH2), 3.46 (q, J = 6.4 Hz, 2H, CH2), 3.21–3.13 (m, 2H, CH2), 1.87–1.76 (m, 4H, CH2),
1.50 (s, 9H, CH3), 1.38 (s, 9H, CH3), 1.43–1.18 (m, 10H, CH2), 0.85 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (150
MHz, CDCl3): δ 192.6 (CO), 163.7 (CO), 163.0 (CN), 157.4 (CO), 153.3 (CO), 141.2 (ArC), 139.1 (ArC),
135.6 (ArC), 135.0 (ArCH), 133.5 (ArCH), 129.1 (ArCH), 127.9 (ArCH), 127.0 (ArCH), 119.0 (ArC), 118.4
(ArCH), 83.8 (C), 79.9 (C), 52.8 (CH2), 37.3 (CH2), 35.9 (CH2), 31.8 (CH2), 30.1 (CH2), 29.1 (CH2), 29.0
(CH2), 28.4 (CH2), 28.3 (CH3), 28.2 (CH3), 23.6 (CH2), 22.7 (CH2), 14.2 (CH3); IR (ATR): νmax 3323, 2928,
2360, 1979, 1720, 1638, 1571, 1508, 1483, 1450, 1410, 1366, 1328, 1284, 1228, 1195, 1131, 1051, 1026, 978,




The titled compound was synthesised from N-(3-aminopropyl)-2-(4′-fluoro-4-(octylsulfonamido)-
[1,1′-biphenyl]-3-yl)-2-oxoacetamide hydrochloride 19b (0.24 g, 0.45 mmol), N,N′-di-Boc-1H-pyrazole-
1-carboxamidine (0.20 g, 0.64 mmol) and triethylamine (0.16 mL, 1.11 mmol) following general synthetic
procedure H. The product was obtained as a yellow solid (0.25, 77%); mp 62.8–65.0 ◦C; 1H NMR
(400 MHz, CDCl3): δ 11.47 (bs, 1H, NH), 10.61 (bs, 1H, NH), 8.64 (t, J = 6.0 Hz, 1H, NH), 8.58 (bs, 1H,
NH), 8.52 (d, J = 2.1 Hz, 1H, ArH), 7.85 (t, J = 7.9 Hz, 1H, ArH), 7.76 (dd, J = 8.7, 2.2 Hz, 1H, ArH),
7.56–7.49 (m, 2H, ArH), 7.13 (t, J = 8.6 Hz, 2H, ArH), 3.63–3.53 (m, 2H, CH2), 3.46 (q, J = 6.2 Hz, 2H,
CH2), 3.20–3.13 (m, 2H, CH2), 1.86–1.76 (m, 4H, CH2), 1.50 (s, 9H, CH3), 1.38 (s, 9H, CH3), 1.43–1.16 (m,
10H, CH2), 0.85 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3): δ 192.3 (CO), 163.6 (CO), 162.8
(ArC), 162.7 (CN), 157.3 (CO), 153.3 (CO), 141.1 (ArC), 135.3 (ArC), 134.7 (ArCH), 134.7 (ArC), 133.3
(ArCH), 128.6 (ArCH), 119.1 (ArC), 118.5 (ArCH), 116.1 (ArCH), 83.9 (C), 80.1 (C), 52.8 (CH2), 37.3
(CH2), 35.9 (CH2), 31.8 (CH2), 30.0 (CH2), 29.1 (CH2), 29.0 (CH2), 28.4 (CH2), 28.2 (CH3), 28.2 (CH3),
23.5 (CH2), 22.7 (CH2), 14.2 (CH3); IR (ATR): νmax 3324, 2926, 2855, 2322, 1890, 1720, 1638, 1570, 1487,
1408, 1326, 1258, 1225, 1128, 1049, 906, 858, 800, 731, 669 cm−1; HRMS ( + ESI): Found m/z 734.3594 [M +
H] +, C36H53FN5O8S required 734.3593.
(E)-1-tert-Butyl-N-(N′-((tert-butyloxidanyl)carbonyl)-N-(3-(2-(4′-chloro-4-(octylsulfonamido)-[1,
1′-biphenyl]-3-yl)-2-oxoacetamido)propyl)carbamimidoyl)-1-oxidanecarboxamide (21c)
The titled compound was synthesised from N-(3-aminopropyl)-2-(4′-chloro-4-(octylsulfonamido)-
[1,1′-biphenyl]-3-yl)-2-oxoacetamide hydrochloride 19c (0.16 g, 0.29 mmol), N,N′-di-Boc-1H-pyrazole-
1-carboxamidine (0.12 g, 0.38 mmol) and triethylamine (0.10 mL, 0.72 mmol) following general synthetic
procedure H. The product was obtained as a yellow solid (0.14 g, 64%); mp 77.1–77.4 ◦C; 1H NMR
(400 MHz, CDCl3): δ 11.47 (bs, 1H, NH), 10.63 (bs, 1H, NH), 8.65 (t, J = 6.3 Hz, 1H, NH), 8.61–8.51 (m,
2H, NH, ArH), 7.86 (d, J = 8.7 Hz, 1H, ArH), 7.77 (dd, J = 8.7, 2.2 Hz, 1H, ArH), 7.52–7.47 (m, 2H, ArH),
7.43–7.39 (m, 2H, ArH), 3.62–3.52 (m, 2H, CH2), 3.46 (q, J = 6.3 Hz, 2H, CH2), 3.20–3.13 (m, 2H, CH2),
1.86–1.75 (m, 4H, CH2), 1.50 (s, 9H, CH3), 1.38 (s, 9H, CH3), 1.43–1.18 (m, 10H, CH2), 0.85 (t, J = 7.1 Hz,
3H, CH3); 13C NMR (150 MHz, CDCl3): δ 192.3 (CO), 163.5 (CO), 163.1 (CN), 157.5 (CO), 153.4 (CO),
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141.5 (ArC), 137.6 (ArC), 134.7 (ArCH), 134.3 (ArC), 134.1 (ArC), 133.4 (ArCH), 129.3 (ArCH), 128.2
(ArCH), 118.9 (ArC), 118.4 (ArCH), 83.8 (C), 79.8 (C), 52.9 (CH2), 37.2 (CH2), 35.9 (CH2), 31.8 (CH2),
30.1 (CH2), 29.1 (CH2), 29.0 (CH2), 28.4 (CH2), 28.3 (CH3), 28.2 (CH3), 23.6 (CH2), 22.7 (CH2), 14.2
(CH3); IR (ATR): νmax 3322, 2929, 1720, 1637, 1577, 1507, 1482, 1409, 1367, 1328, 1285, 1253, 1228, 1195,
1131, 1094, 1050, 1026, 1012, 979, 907, 856, 817, 770, 698, 657, 592, 562, 489, 419 cm−1; HRMS (+ ESI):
Found m/z 772.3120 [M + Na] +, C36H52ClN5O8SNa required 772.3117.
(E)-1-tert-Butyl-N-(N′-((tert-butyloxidanyl)carbonyl)-N-(3-(2-(5-(naphthalen-2-yl)-2-(octylsulfonamido)
phenyl)-2-oxoacetamido)propyl)carbamimidoyl)-1-oxidanecarboxamide (21d)
The titled compound was synthesised from N-(3-Aminopropyl)-2-(5-(naphthalen-2-yl)-2-
(octylsulfonamido)phenyl)-2-oxoacetamide hydrochloride 19d (0.18 g, 0.33 mmol), N,N′-di-Boc-1H
-pyrazole-1-carboxamidine (0.13 g, 0.40 mmol) and triethylamine (0.12 mL, 0.83 mmol) following general
synthetic procedure H. The product was obtained as a yellow solid (0.13 g, 52%); mp 71.6–73.5 ◦C;
1H NMR (400 MHz, CDCl3): δ 11.47 (bs, 1H, NH), 10.66 (bs, 1H, NH), 8.71–8.53 (m, 3H, NH, ArH),
8.01 (s, 1H, ArH), 7.98–7.84 (m, 5H, ArH), 7.71 (dd, J = 8.5, 1.7 Hz, 1H, ArH), 7.55–7.46 (m, 2H, ArH),
3.64–3.54 (m, 2H, CH2), 3.48 (q, J = 6.2 Hz, 2H, CH2), 3.23–3.15 (m, 2H, CH2), 1.89–1.76 (m, 4H, CH2),
1.50 (s, 9H, CH3), 1.39 (s, 9H, CH3), 1.44–1.17 (m, 10H, CH2), 0.85 (t, J = 7.1 Hz, 3H, CH3); 13C NMR
(100 MHz, CDCl3): δ 192.6 (CO), 163.8 (CO), 162.8 (CN), 157.3 (CO), 153.3 (CO), 141.2 (ArC), 136.4
(ArC), 135.6 (ArC), 135.2 (ArC), 133.7 (ArCH), 133.7 (ArCH), 132.9 (ArC), 128.9 (ArCH), 128.3 (ArCH),
127.8 (ArCH), 126.7 (ArCH), 126.4 (ArCH), 125.7 (ArCH), 125.1 (ArCH), 119.2 (ArC), 118.5 (ArCH), 83.9
(C), 80.2 (C), 52.8 (CH2), 37.5 (CH2), 35.9 (CH2), 31.8 (CH2), 30.0 (CH2), 29.1 (CH2), 29.0 (CH2), 28.3
(CH2), 28.3 (CH3), 28.2 (CH3), 23.6 (CH2), 22.7 (CH2), 14.2 (CH3); IR (ATR): νmax 3323, 2928, 2360, 1979,
1720, 1638, 1571, 1508, 1483, 1450, 1410, 1366, 1328, 1284, 1228, 1195, 1131, 1051, 1026, 978, 907, 855, 806,
760, 697, 681, 616, 587, 562, 537, 418 cm−1; HRMS (+ ESI): Found m/z 766.3845 [M + H] +, C40H56N5O8S
required 766.3844.
General Synthetic Procedure I for Guanidinium Hydrochloride Salts
To a solution of Boc-protected guanidine glyoxamide (1.0 equivalent) in dichloromethane (1 mL),
trifluoroacetic acid (1 mL) was added. The reaction mixture was stirred at room temperature for 3 h.
After completion of the reaction, the reaction mixture was concentrated in vacuo and washed thrice
with diethyl ether. To the residue in dichloromethane (1 mL), 4 M HCl/dioxane (1 mL) was added.
The reaction mixture was stirred at room temperature for 30 min. After completion of reaction, the




The titled compound was synthesised from (E)-1-tert-Butyl-N-(N′-((tert-butyloxidanyl)
carbonyl)-N-(3-(2-(4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamido)propyl)carbamimidoyl)
-1-oxidanecarboxamide 21a (40 mg, 0.056 mmol) following general synthetic procedure I. The product
was obtained as a yellow sticky solid (0.15 g, 50%); 1H NMR (600 MHz, DMSO-d6): δ 10.20 (bs, 1H,
NH), 9.01 (t, J = 5.7 Hz, 1H, NH), 8.03–7.99 (m, 2H, ArH), 7.69–7.61 (m, 4H, NH, ArH), 7.57–6.78 (m,
7H, NH, ArH), 3.30 (q, J = 6.5 Hz, 2H, CH2), 3.28–3.23 (m, 2H, CH2), 3.19 (q, J = 6.5 Hz, 2H, CH2),
1.79–1.63 (m, 4H, CH2), 1.37–1.29 (m, 2H, CH2), 1.26–1.15 (m, 8H, CH2), 0.82 (t, J = 7.1 Hz, 3H, CH3);
13C NMR (150 MHz, DMSO-d6): δ 192.6 (CO), 163.8 (CO), 156.9 (CN), 138.3 (ArC), 138.2 (ArC), 135.6
(ArC), 133.2 (ArCH), 130.5 (ArCH), 129.2 (ArCH), 127.9 (ArCH), 126.4 (ArCH), 124.5 (ArC), 121.6
(ArCH), 51.4 (CH2), 38.4 (CH2), 36.1 (CH2), 31.1 (CH2), 28.4 (CH2), 28.4 (CH2), 28.3 (CH2), 27.3 (CH2),
22.9 (CH2), 22.0 (CH2), 13.9 (CH3); IR (ATR): νmax 3364, 3163, 2924, 2654, 2360, 1626, 1581, 1528, 1510,
1485, 1459, 1395, 1345, 1265, 1198, 1139, 1067, 924, 909, 849, 759, 683, 621, 587, 560, 530, 481, 424 cm−1;
HRMS (+ ESI): Found m/z 516.2636 [M + H] +, C26H38N5O4S required 516.2639.
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2-(4′-Fluoro-4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-N-(3-guanidinopropyl)-2-oxoacetamide
hydrochloride (22b)
The titled compound was synthesised from (E)-1-tert-Butyl-N-(N′-((tert-butyloxidanyl)carbonyl)-
N-(3-(2-(4′-fluoro-4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamido)propyl)carbamimidoyl)
-1-oxidanecarboxamide 21b (0.10 g, 0.13 mmol) following general synthetic procedure I. The product
was obtained as a yellow sticky solid (49 mg, 61%); 1H NMR (600 MHz, DMSO-d6): δ 10.19 (bs, 1H,
NH), 9.01 (t, J = 5.9 Hz, 1H, NH), 8.00–7.96 (m, 2H, ArH), 7.74 (t, J = 5.8 Hz, 1H, NH), 7.71–7.66 (m, 2H,
ArH), 7.64–7.60 (m, 1H, ArH), 7.58–6.80 (m, 6H, NH, ArH), 3.30 (q, J = 6.7 Hz, 2H, CH2), 3.26–3.22 (m,
2H, CH2), 3.20 (q, J = 6.7 Hz, 2H, CH2), 1.77–1.71 (m, 2H, CH2), 1.70–1.63 (m, 2H, CH2), 1.36–1.30 (m,
2H, CH2), 1.26–1.15 (m, 8H, CH2), 0.82 (t, J = 7.2 Hz, 3H, CH3); 13C NMR (150 MHz, DMSO-d6): δ
192.4 (CO), 163.7 (CO), 162.1 (ArC), 157.0 (CN), 138.2 (ArC), 134.7 (ArC), 134.6 (ArC), 133.0 (ArCH),
130.4 (ArCH), 128.5 (ArCH), 124.6 (ArC), 121.8 (ArCH), 116.0 (ArCH), 51.4 (CH2), 38.4 (CH2), 36.1
(CH2), 31.1 (CH2), 28.4 (CH2), 28.4 (CH2), 28.3 (CH2), 27.3 (CH2), 22.9 (CH2), 22.0 (CH2), 13.9 (CH3);
IR (ATR): νmax 3313, 3155, 2923, 2853, 2292, 1910, 1639, 1487, 1396, 1330, 1195, 1137, 913, 826, 722 cm−1;
HRMS (+ ESI): Found m/z 534.2544 [M + H] +, C26H37FN5O4S required 534.2545.
2-(4′-Chloro-4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-N-(3-guanidinopropyl)-2-oxoacetamide
hydrochloride (22c)
The titled compound was synthesised from (E)-1-tert-butyl-N-(N′-((tert-butyloxidanyl)carbonyl)-
N-(3-(2-(4′-chloro-4-(octylsulfonamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamido)propyl)carbamimidoyl)
-1-oxidanecarboxamide 21c (91 mg, 0.12 mmol) following general synthetic procedure I. The product
was obtained as a yellow sticky solid (43 mg, 60%); 1H NMR (600 MHz, DMSO-d6): δ 10.20 (bs, 1H,
NH), 9.00 (t, J = 5.8 Hz, 1H, NH), 8.03–7.98 (m, 2H, ArH), 7.71–7.66 (m, 3H, NH, ArH), 7.63 (dd,
J = 7.6, 1.5 Hz, 1H, ArH), 7.58–7.54 (m, 2H, ArH), 7.52–6.84 (bs, 4H, NH), 3.30 (q, J = 6.7 Hz, 2H,
CH2), 3.27–3.22 (m, 2H, CH2), 3.19 (q, J = 6.6 Hz, 2H, CH2), 1.77–1.71 (m, 2H, CH2), 1.70–1.63 (m,
2H, CH2), 1.36–1.30 (m, 2H, CH2), 1.26–1.15 (m, 8H, CH2), 0.82 (t, J = 7.2 Hz, 3H, CH3); 13C NMR
(150 MHz, DMSO-d6): δ 192.3 (CO), 163.7 (CO), 156.9 (CN), 138.5 (ArC), 137.1 (ArC), 134.2 (ArC),
133.0 (ArCH), 132.8 (ArC), 130.4 (ArCH), 129.2 (ArCH), 128.2 (ArCH), 124.7 (ArC), 121.8 (ArCH), 51.5
(CH2), 38.4 (CH2), 36.1 (CH2), 31.1 (CH2), 28.4 (CH2), 28.4 (CH2), 28.3 (CH2), 27.3 (CH2), 22.9 (CH2),
22.0 (CH2), 13.9 (CH3); IR (ATR): νmax 3164, 2925, 2854, 2360, 1640, 1534, 1507, 1481, 1397, 1332, 1273,




The titled compound was synthesised from (E)-1-tert-butyl-N-(N′-((tert-butyloxidanyl)carbonyl)
-N-(3-(2-(5-(naphthalen-2-yl)-2-(octylsulfonamido)phenyl)-2-oxoacetamido)propyl)carbamimidoyl)
-1-oxidanecarboxamide 21d (0.10 g, 0.13 mmol) following general synthetic procedure I. The product
was obtained as a yellow sticky solid (49 mg, 61%); 1H NMR (600 MHz, DMSO-d6): δ 10.22 (bs, 1H,
NH), 9.03 (t, J = 5.8 Hz, 1H, NH), 8.21 (s, 1H, ArH), 8.17–8.14 (m, 2H, ArH), 8.07–7.94 (m, 3H, ArH),
7.81 (dd, J = 8.5, 1.9 Hz, 1H, ArH), 7.73 (t, J = 6.0 Hz, 1H, NH), 7.69–7.66 (m, 1H, ArH), 7.62–6.80 (m,
6H, NH, ArH), 3.32 (q, J = 6.8 Hz, 2H, CH2), 3.28–3.24 (m, 2H, CH2), 3.21 (q, J = 6.8 Hz, 2H, CH2),
1.79–1.72 (m, 2H, CH2), 1.72–1.65 (m, 2H, CH2), 1.38–1.31 (m, 2H, CH2), 1.27–1.15 (m, 8H, CH2), 0.81 (t,
J = 7.2 Hz, 3H, CH3); 13C NMR (150 MHz, DMSO-d6): δ 192.6 (CO), 163.8 (CO), 157.0 (CN), 138.2
(ArC), 135.6 (ArC), 135.5 (ArC), 133.3 (ArCH), 133.2 (ArC), 132.4 (ArC), 130.6 (ArCH), 128.8 (ArCH),
128.2 (ArCH), 127.6 (ArCH), 126.7 (ArCH), 126.4 (ArCH), 125.2 (ArCH), 125.0 (ArC), 124.6 (ArCH),
122.0 (ArCH), 51.4 (CH2), 38.4 (CH2), 36.1 (CH2), 31.1 (CH2), 28.4 (CH2), 28.4 (CH2), 28.3 (CH2), 27.3
(CH2), 22.9 (CH2), 22.0 (CH2), 13.9 (CH3); IR (ATR): νmax 3324, 3159, 3055, 2923, 2853, 2321, 2112, 1924,
1747, 1639, 1493, 1463, 1396, 1328, 1267, 1139, 1189, 913, 814 cm−1; HRMS (+ ESI): Found m/z 566.2793
[M + H] +, C30H40N5O4S required 566.2796.
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1-(2-Naphthoyl)-5-phenylindoline-2,3-dione (24)
To a suspension of sodium hydride (90 mg, 2.25 mmol) in dimethylformamide (5 mL),
slowly dropwise, a solution of 5-phenylindoline-2,3-dione 7a (0.43 g, 1.92 mmol) in dimethylformamide
(5 mL) was added at 0 ◦C under nitrogen atmosphere. The reaction mixture was stirred at 0 ◦C for
15 min. A solution of 2-naphthoyl chloride (0.38 g, 2.01 mmol) in dimethylformamide (7 mL) was
then added slowly dropwise to the reaction mixture at 0 ◦C with stirring. The reaction mixture was
then stirred at room temperature for 3 h. After completion of the reaction, the resulting mixture was
poured into 1:1 ice-water mixture. The yellow precipitate was then collected via vacuum filtration
and washed with methanol to afford the product as yellow solid (0.25 g, 35%); mp 127.4–127.5 ◦C;
1H NMR (600 MHz, DMSO-d6): δ 8.60 (d, J = 1.2 Hz, 1H, ArH), 8.16 (dd, J = 8.5, 2.2 Hz, 1H, ArH),
8.09–8.03 (m, 5H, ArH), 7.95 (dd, J = 8.5, 1.7 Hz, 1H, ArH), 7.80–7.77 (m, 2H, ArH), 7.73–7.69 (m, 1H,
ArH), 7.67–7.63 (m, 1H, ArH), 7.54–7.50 (m, 2H, ArH), 7.45–7.41 (m, 1H, ArH); 13C NMR (150 MHz,
DMSO-d6): δ 180.2 (CO), 168.0 (CO), 157.4 (CO), 147.3 (ArC), 138.2 (ArC), 137.2 (ArC), 135.6 (ArCH),
135.0 (ArC), 131.8 (ArC), 131.2 (ArCH), 131.1 (ArC), 129.2 (ArCH), 129.2 (ArCH), 128.7 (ArCH), 128.1
(ArCH), 127.8 (ArCH), 127.6 (ArCH), 127.0 (ArCH), 126.6 (ArCH), 125.5 (ArCH), 121.9 (ArCH), 120.7
(ArC), 116.7 (ArCH); IR (ATR): νmax 3854, 3675, 2987, 2900, 1948, 1762, 1739, 1692, 1615, 1589, 1508,
1473, 1458, 1406, 1393, 1357, 1306, 1285, 1223, 1193, 1161, 1122, 1066, 1057, 1027, 990, 967, 953, 928, 904,
890, 868, 856, 828, 793, 776, 760, 717, 704, 691, 622, 584, 541, 516, 481, 463 cm−1; HRMS (+ ESI): Found
m/z 400.0945 [M + Na] +, C25H15NO3Na required 400.0944.
N-(3-(2-((3-(Dimethylamino)propyl)amino)-2-oxoacetyl)-[1,1′-biphenyl]-4-yl)-2-naphthamide (25)
To a solution of 1-(2-naphthoyl)-5-phenylindoline-2,3-dione 24 (0.11 g, 0.30 mmol) in
dichloromethane (5 mL), 3-dimethylaminopropylamine (38 µL, 0.30 mmol) was added at 0 ◦C.
The reaction mixture was stirred at room temperature for 6 h. After completion of the reaction, water
was added to the reaction mixture and the product was extracted into dichloromethane (3 × 30 mL),
washed with brine, dried over anhydrous sodium sulphate and concentrated in vacuo to afford the
product as a yellow solid (0.13 g, 93%); mp 151.6–151.8 ◦C; 1H NMR (600 MHz, CDCl3): δ 12.21 (bs, 1H,
NH), 9.05 (d, J = 9.0 Hz, 1H, ArH), 8.71 (d, J = 2.2 Hz, 1H, ArH), 8.60 (bs, 1H, NH), 8.58 (d, J = 1.3 Hz,
1H, ArH), 8.10 (dd, J = 8.6, 2.0 Hz, 1H, ArH), 8.02 (dd, J = 7.2, 0.6 Hz, 1H, ArH), 7.98 (d, J = 8.6 Hz, 1H,
ArH), 7.95–7.90 (m, 2H, ArH), 7.64–7.56 (m, 4H, ArH), 7.48–7.44 (m, 2H, ArH), 7.39–7.35 (m, 1H, ArH),
3.57 (q, J = 5.7 Hz, 2H, CH2), 2.54 (t, J = 6.4 Hz, 2H, CH2), 2.32 (s, 6H, CH3), 1.87–1.81 (m, 2H, CH2); 13C
NMR (150 MHz, CDCl3): δ 193.1 (CO), 166.1 (CO), 163.4 (CO), 141.8 (ArC), 139.5 (ArC), 135.7 (ArC),
135.2 (ArC), 135.2 (ArCH), 133.1 (ArCH), 132.9 (ArC), 131.9 (ArC), 129.5 (ArCH), 129.1 (ArCH), 128.9
(ArCH), 128.6 (ArCH), 128.2 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.0 (ArCH), 127.0 (ArCH), 123.8
(ArCH), 121.4 (ArCH), 119.6 (ArC), 58.5 (CH2), 45.3 (CH3), 39.6 (CH2), 25.6 (CH2); IR (ATR): νmax 3854,
3675, 3309, 2972, 2900, 2780, 1762, 1735, 1679, 1644, 1627, 1585, 1522, 1492, 1472, 1449, 1394, 1341, 1301,
1285, 1222, 1191, 1132, 1065, 1027, 965, 910, 890, 858, 818, 775, 758, 697, 679, 609, 572, 539, 512, 483, 466,
446 cm−1; HRMS ( + ESI): Found m/z 480.2283 [M + H] +, C30H30N3O3 required 480.2282.
3-(2-(4-(2-Naphthamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamido)-N,N-dimethylpropan-1-aminium
chloride (26)
To a solution of N-(3-(2-((3-(dimethylamino)propyl)amino)-2-oxoacetyl)-[1,1′-biphenyl]-4-yl)-
2-naphthamide 25 (32 mg, 0.067 mmol) in dichloromethane (5 mL), 4 M HCl/dioxane (0.10 mL, 0.40
mmol) was added. The reaction mixture was stirred at room temperature for 20 min. After completion
of reaction, the reaction mixture was concentrated in vacuo, washed thrice with diethyl ether and
freeze-dried to afford the product as a yellow sticky solid (29 mg, 84%); 1H NMR (600 MHz, DMSO-d6):
δ 11.43 (s, 1H, NH), 10.38 (bs, 1H, NH), 9.01 (t, J = 6.1 Hz, 1H, NH), 8.63 (s, 1H, ArH), 8.18–8.10 (m, 3H,
ArH), 8.07–8.01 (m, 4H, ArH), 7.73–7.64 (m, 4H, ArH), 7.52 (t, J = 7.9 Hz, 2H, ArH), 7.41 (t, J = 7.3 Hz,
2H, ArH), 3.24 (q, J = 6.7 Hz, 2H, CH2), 3.02–2.97 (m, 2H, CH2), 2.63 (s, 6H, CH3), 1.87–1.79 (m, 2H,
CH2); 13C NMR (150 MHz, DMSO-d6): δ 190.6 (CO), 165.5 (CO), 163.2 (CO), 138.6 (ArC), 137.6 (ArC),
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135.6 (ArC), 134.5 (ArC), 132.1 (ArC), 131.9 (ArCH), 131.2 (ArC), 129.3 (ArCH), 129.2 (ArCH), 129.1
(ArCH), 128.5 (ArCH), 128.2 (ArCH), 128.2 (ArCH), 127.8 (ArCH), 127.8 (ArCH), 127.1 (ArCH), 126.5
(ArCH), 125.5 (ArC), 123.9 (ArCH), 123.0 (ArCH), 54.3 (CH2), 41.9 (CH3), 36.0 (CH2), 23.8 (CH2); IR
(ATR): νmax 3331, 3056, 2963, 2681, 2361, 1676, 1643, 1626, 1585, 1523, 1493, 1448, 1396, 1368, 1341, 1306,
1286, 1245, 1219, 1189, 1133, 1068, 967, 912, 891, 849, 819, 761, 699, 681, 572, 512, 487 cm−1; HRMS (+ ESI):
Found m/z 480.2281 [M + H] +, C30H30N3O3 required 480.2282.
3-(2-(4-(2-Naphthamido)-[1,1′-biphenyl]-3-yl)-2-oxoacetamido)-N,N,N-trimethylpropan-1-aminium
iodide (27)
To a solution of N-(3-(2-((3-(dimethylamino)propyl)amino)-2-oxoacetyl)-[1,1′-biphenyl]-4-yl)-
2-naphthamide 25 (34 mg, 0.071 mmol) in THF (5 mL), iodomethane (11 µL, 0.18 mmol) was added.
The reaction mixture was stirred at room temperature for 24 h. After completion of reaction, the reaction
mixture was concentrated in vacuo, washed thrice with diethyl ether and freeze-dried to afford the
product as a yellow sticky solid (35 mg, 79%); 1H NMR (600 MHz, DMSO-d6): δ 10.37 (bs, 1H, NH),
8.98 (t, J = 6.0 Hz, 1H, NH), 8.61 (d, J = 1.1 Hz, 1H, ArH), 8.14–8.08 (m, 3H, ArH), 8.07–8.01 (m, 4H,
ArH), 7.73–7.64 (m, 4H, ArH), 7.54–7.49 (m, 2H, ArH), 7.44–7.40 (m, 1H, ArH), 3.30–3.25 (m, 2H, CH2),
3.23 (q, J = 6.6 Hz, 2H, CH2), 2.95 (s, 9H, CH2), 1.90–1.82 (m, 2H, CH2); 13C NMR (150 MHz, DMSO-d6):
δ 190.3 (CO), 165.6 (CO), 163.0 (CO), 138.7 (ArC), 137.4 (ArC), 135.6 (ArC),134.5 (ArC), 132.1 (ArC),
131.8 (ArCH), 131.3 (ArC), 129.3 (ArCH), 129.2 (ArCH), 129.0 (ArCH), 128.5 (ArCH), 128.3 (ArCH),
128.2 (ArCH), 127.8 (ArCH), 127.8 (ArCH), 127.2 (ArCH), 126.5 (ArCH), 125.8 (ArC), 123.9 (ArCH),
123.1 (ArCH), 63.3 (CH2), 52.2 (CH3), 35.9 (CH2), 22.5 (CH2); IR (ATR): νmax 3319, 2999, 2360, 2160,
1978, 1677, 1644, 1625, 1586, 1525, 1494, 1447, 1399, 1342, 1306, 1286, 1198, 1068, 966, 912, 868, 850, 825,
763, 698, 681, 609, 573, 517, 488, 472, 426 cm−1; HRMS (+ ESI): Found m/z 494.2439 [M] +, C31H32N3O3
required 494.2438.
3.2. Minimum Inhibitory Concentration (MIC) Assay
The antimicrobial activity of the compounds was evaluated by MIC assay using the procedure
described by Clinical and Laboratory Standards Institute (CLSI). A single colony of bacteria was cultured
overnight in trypticase soy broth (TSB; Oxoid, Basingstoke, UK) at 37 ◦C with shaking. The resulting
bacterial culture was collected by centrifugation and resuspended in TSB twice. The optical density
(OD) of the resulting culture was adjusted to OD660 = 0.1 in TSB (which is equivalent to 108 colony
forming unit (CFU)/mL bacteria). It was further diluted to 106 CFU/mL in TSB. 100 µL of the bacterial
solution was then added to wells of a 96-well plate (Costar; Sigma-Aldrich, St Louis, MO, USA)
containing 100 µL serially diluted peptide mimic, with final concentration ranging from 1 to 250 µM.
Wells with bacteria but no compound were used as negative control while wells with only media
were set as blank. The plates were then wrapped with parafilm to prevent evaporation and incubated
with shaking at 120 rpm at 37 ◦C for 18–24 h, and the data were recorded by measuring the OD
value at 660 nm using a FLUOstar Omega (BMG Labtech, Mornington, Victoria, Australia) microplate
reader. The MIC value of each compound was determined as the lowest concentration that completely
inhibited the growth of bacteria. Each experiment was performed in triplicate and was repeated in
three independent experiments.
3.3. Biofilm Disruption Assay
Bacterial cultures (S. aureus and E. coli) were grown in Muller Hinton broth (MHB; Oxoid,
Basingstoke, UK) media overnight at 37 ◦C with shaking at 120 rpm. Cultures were diluted (1:20)
in MHB medium and 200 µL aliquots were dispensed to wells in a flat bottom 96-well plate (Costar;
Sigma-Aldrich, St Louis, MO, USA). Biofilm was then grown in the 96-well plate at 37 ◦C overnight.
After that, loosely bound cells were washed away with 1x phosphate-buffered saline (PBS) and cultures
were then supplemented with different concentrations of test compounds dissolved in DMSO and
incubated for a further 24 h with shaking at 120 rpm. Biofilms adhered on the plate substratum were
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quantified using crystal violet staining as described previously [18,63]. The experiment was performed
in triplicate.
3.4. Cytoplasmic Membrane Permeability Assay
Bacterial cytoplasmic membrane permeability was determined using membrane potential-sensitive
dye diSC3–5 (3,3′-dipropylthiadicarbocyanine iodide), which penetrates inside bacterial cells depending
on the membrane potential gradient of the cytoplasmic membrane. The procedure of this assay follows
the method previously described by Wu et al. [64] with slight modifications. Bacteria were grown in
MHB to mid-log phase by incubating with shaking at 37 ◦C for 16 h. Following incubation, bacteria
were washed with 5 mM HEPES containing 20 mM glucose at pH 7.2 and resuspended in the same
buffer to an OD600 0.05–0.06 (yielding a final concentration of 107 CFU/mL). The dye diSC3–5 was
added at 4 µM to the bacterial suspension. The suspensions were incubated at room temperature
for 1 h in darkness for maximum dye take-up by the bacterial cells. 100 mM KCl was then added to
balance the K+ outside and inside the bacterial cell. 100 µL of bacterial suspension was added in a
96-well microtiter plate and with equal volume of antimicrobial compounds. DMSO (10%) was set as a
positive control while dye and only bacterial cells were set as negative control. Fluorescence due to
release of dye was measured with a luminescence spectrophotometer at 3 min intervals at an excitation
wavelength of 621 nm and an emission wavelength of 670 nm.
3.5. Cell Viability Count Assay
The number of viable cells was confirmed by serially diluting aliquots of bacteria in D/E neutralizing
broth (Remel, Lenexa, KS, USA) and plating onto Tryptic Soy Agar (Oxoid, Basingstoke, UK) containing
phosphatidylcholine (0.7 g/L) and Tween 80 (5 mL/L). The plates were incubated at 37 ◦C overnight and
numbers of live bacteria were enumerated and expressed as CFU/mL. The experiment was performed
in triplicate [36].
3.6. Tethered Bilayer Lipid Membranes (tBLMs) Assay
Changes in membrane conduction and capacitance were measured using tethered bilayer lipid
membranes (tBLMs) in association with AC electrical impedance spectroscopy techniques [60,65]. Sparsely
tethered tBLMs were prepared using a zwitterionic 1-palmitoyl-2-oleoyl-glycero- 3-phosphocholine
(POPC) (Avanti Lipids, USA) or a mixture of 30% palmitoyl-oleoyl-phosphatidylglycerol (POPG)
(Avanti Lipids, USA) lipids with 70% POPC in order to create a negatively charged tBLM [66,67].
To do this, gold-patterned polycarbonate slides were coated with tethered benzyl-disulfide (tetra-
ethyleneglycol) n = 2 C20-phytanyl tethers:benzyl-disulfide-tetra-ethyleneglycol-OH spacers in the
ratio of 1:10 (SDx Tethered Membranes Pty Ltd., Australia). A 3 mM solution of a mobile lipid phase
POPC, or a 3 mM solution of mobile phase POPC/POPG (70:30), (Avanti Lipids, USA) in 100% ethanol
was then incubated with the tethering chemistries. Lipids were left to incubate with the tethering
chemistries for 2 min before being washed with 3 × 400 mL of phosphate-buffered saline (PBS). Prior to
the addition of the compounds, membrane stability was confirmed by 5 × 100 µL washes of the
PBS vehicle. AC electrical impedance spectrometry (EIS) was then used to monitor any changes in
membrane impedances as a result of adding the test compounds in increasing concentrations.
For EIS measures, a 50 mV peak-to-peak AC excitation from 0.1 to 2000 Hz with four steps
per decade were recorded using a TethaPod™ operated with TethaQuick™ software (SDx Tethered
Membranes Pty Ltd., Australia). The data were fitted to an equivalent circuit consisting of a Constant
Phase Element (CPE), to represent the imperfect capacitance of the gold tethering electrode, in series
with a Resistor/Capacitor network to represent the lipid bilayer membrane [60]. Fitting of the phase
and impedance data to the equivalent circuit was completed with a proprietary adaptation of a Lev
Mar fitting routine. To account for variations in basal membrane conditions, data are normalised to a
baseline conduction and capacitance values directly before the addition of each compound.
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3.7. Toxicity Assay
The toxicity of the compounds was measured using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide) (Sigma Aldrich, St Louis, MO, USA) colorimetric assay against
normal human lung fibroblasts MRC-5 cells. The cells were cultured in minimal essential medium
(MEM; Sigma Aldrich, St Louis, MO, USA) containing 10% foetal bovine serum (FBS). The cells were
maintained at 37 ◦C in 5% CO2 as an adherent monolayer and was passaged upon reaching confluence
by standard cell culture techniques. MRC-5 cells were seeded at 5000 cells/well in 96-well plates to
ensure full confluence (quiescence) and left overnight to adhere to the plate wells. The adherent cells
were treated with 1–500 µM of compounds by dissolving in DMSO and serially diluting with media.
The final concentration of DMSO was 0.5% (v/v). After 72 h drug incubation, 20 mL stock MTT solution
(5 mg/mL) was added and the cells were incubated for another 3.5–4 h. MTT solution-containing
media was carefully aspirated without displacing the purple crystals from the bottom and 80 mL
acid-isopropanol was added to all wells and mixed slowly by shaking with an orbital shaker to dissolve
the dark blue crystals. The metabolic activity was detected by spectrophotometric analysis by assessing
the read absorbance (590/620 nm) on an EnSight plate reader (PerkinElmer, Waltham, MA, USA) and
cell viability was expressed as a percentage of untreated control cells. The determination of IC50 values
was performed using GraphPad Prism 6 (GraphPad, San Diego, CA, USA). Each experiment was
performed in triplicate and was repeated in three independent experiments.
4. Conclusions
A library of biphenylglyoxamide-based small molecular AMP mimics was successfully synthesised
from different 5-arylisatins. Hydrophobicity was introduced to the AMP via N-sulfonylation of
5-arylisatins. The ring-opening reaction of N-sulfonylisatins followed by the conversion of the
resulting glyoxamide derivatives into tertiary ammonium chloride, quaternary ammonium iodide
or guanidinium hydrochloride salts conferred the cationicity of the AMP mimics. An in vitro
antibacterial assay demonstrated that these AMP mimics possessed excellent antibacterial activities
against Gram-positive S. aureus. Additionally, the quaternary ammonium iodide salts 15a–15c and
guanidinium hydrochloride salts 22a–22c also showed moderate to high antibacterial activities against
Gram-negative P. aeruginosa and E. coli. SAR studies revealed that the octanesulfonyl group was
essential for Gram-positive antibacterial activity, while both the octanesulfonyl group and the biphenyl
backbone were important for Gram-negative antibacterial activity. The most potent compounds,
15c, 22b and 22d (MIC = 8 µM against S. aureus), disrupted pre-established S. aureus biofilms by
35%, 39% and 50% respectively, at 32 µM (4×MIC). In a cytoplasmic membrane permeability study,
the chloro-substituted quaternary ammonium iodide salt 15c showed strong ability to disrupt and
depolarise the bacterial cell membrane. These results were consistent with the tethered bilayer lipid
membrane assay, where 15c demonstrated its ability to disintegrate the bilayer lipid membrane. Finally,
an in vitro toxicity assay performed against human MRC-5 fibroblast cells showed that the quaternary
ammonium iodide salts and the guanidinium hydrochloride salts were of low cytotoxicity, with wide
therapeutic windows for bacterial cells over human cells. Overall, this study demonstrated that
biphenylglyoxamide-based quaternary ammonium iodide salts and guanidinium hydrochloride salts
are new leads for the development of the next generation of small molecular AMP mimics that possess
anti-biofilm and membrane disruption properties.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/18/
6789/s1, Figure S1. Percentage of remaining S. aureus biofilms after 24 h treatment with compounds 15d (top),
22a (middle) or 22c (bottom) at 1×, 2× and 4× of their MIC. Error bars represent the standard error of triplicates
(n = 3). Figure S2. Percentage of remaining E. coli biofilms after 24 h treatment with compounds 15c or 22c at 4× of
their MIC (64 µM). Error bars represent the standard error of triplicates (n = 3).
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